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Forward  
The Life Study protocol was developed by the scientific leadership team together with 
experts from a wide range of disciplines drawn from the biomedical, clinical and social 
science research communities who formed part of a wider affiliated scientific network. The 
protocol sets out the key research themes of the study, chosen to capitalise on the unique 
opportunities afforded by the Study design, and to enable a wide range of research 
questions and policy issues relevant to children to be explored. 
The Life Study protocol was initially developed in response to the call specification for bids 
for a leadership team for a new birth cohort study issued by ESRC and MRC in 2009.  This 
call specification was informed by preceding reviews commissioned from Longview by the 
ESRC between 2006 and 2009. Following international peer review and interviews by an 
international panel, ESRC awarded funding to the proposal from the leadership team led by 
Professor Dezateux.  Funding was not released until 2011.   
The Life Study protocol was developed by members of the Scientific Protocol Development 
Group with input from Scientific Working Groups, each co-chaired by social and biomedical 
scientists. Ad hoc subgroups and external experts contributed on focussed aspects. A public 
consultation took place on the draft protocol in July 2012, followed by an independently 
conducted web survey with input from a wide range of disciplines.    The Life Study Scientific 
Steering Committee (members listed below) is responsible for the content of this protocol, 
having approved its final content and any revisions needed in the light of experience 
following piloting.  They, and key members of the Life Study team, are its authors.   
This document sets out the Life Study protocol, approved by the Research Ethics Committee 
in January 2015 when the first Life Study Centre opened and which was in operation at the 
time the decision to close Life Study was taken by the funders in July 2015.  
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1 Overview of Life Study  
 
1.1  Introduction 
Life Study will be the UK’s largest national birth cohort study and will gather data on more 
than 80,000 babies born in the UK, with recruitment beginning in 2014/15. The study has 
been developed by a cross-disciplinary research team, which includes leading biomedical 
and social scientists from across the UK. This document outlines the background, aims and 
methodology of Life Study and provides detailed information about the study protocol and 
first ‘sweep’ of data collection, which will follow babies from the prenatal period until the 
end of the first year of postnatal life. The protocol presented here was approved by the 
Research Ethics Committee in March 2014. Additional documents are available on the Life 
Study website at www.lifestudy.ac.uk.  
The Life Study protocol was initially developed in response to the call specification for bids 
for leadership team for a new birth cohort study issued by ESRC and MRC in 2009.1  This call 
specification (see Appendix 1) was informed by preceding reviews commissioned from 
Longview by the ESRC between 2006 and 2009.2 Following international peer review and 
interviews by an international panel, ESRC awarded funding to the proposal from the 
leadership team led by Professor Dezateux.  Funding was not released until mid-2011.   
1.2 Overview and aims  
Life Study is the first UK-wide study to start in pregnancy so will be able to collect data and 
consider factors before birth. The large size of the study will allow research into the impact 
of children’s early environments on their future development. By following the early lives of 
babies born into today’s society, Life Study will collect unique and rich information to 
answer important questions for children’s health. Particular attention will be given to 
exploring ethnicity, household and family environment, and social and material 
disadvantage, and the interplay between biology and environment. The answers to a wide 
range of research questions and policy-relevant issues will help understand how to improve 
children’s lives and those of future generations. 
                                               
1
 A Leadership Team for the 2012 Birth Cohort Study: Call Specification, April 2009. 
2012_Cohort_Study_Leadership_Team_Specification_tcm6-31588.pdf reproduced at Appendix 1. 
  
2
 (i) Strategic Review of Panel and Cohort Studies, 2006. (ii) Scientific Case for a New Cohort Study, 2007. (iii) 
Options for the Design of the 2012 Birth Cohort Study, 2009. These reports were undertaken by Longview and 
are available for download from http://www.slls.org.uk/#!longview-reports/c8a5.  
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Life Study will involve more than 80,000 UK babies and their families across England, 
Scotland, Wales and Northern Ireland. Women and their partners will be invited to take part 
during pregnancy, or soon after the birth, and they and their new baby (or babies) will be 
seen at Life Study Centres or in their own homes at least once during the first year after the 
birth. The study will observe the children and their families long-term, following the 
example set by previous long-term cohort studies. The design will allow Life Study to be 
compared with earlier UK birth cohorts while exploiting the opportunity to enrich the cohort 
with additional biological data as well as with contextual area-based information.  
1.3 Rationale for Life Study 
Life Study will be the fifth longitudinal birth cohort study in a series of world renowned UK 
studies which have followed the lives of children from birth to adult life. The first of these 
started post-war in 1946 (National Survey of Health and Development), and the most recent 
began at the turn of the 21st Century (Millennium Cohort Study). Since then, the 
demographics of the UK population has changed significantly, and Life Study will enable this 
increased diversity to be taken into account, as well as providing a wealth of insights into 
the health, development and life circumstances of a new generation of children.  
1.4 Research themes 
The aims of the study will be addressed through specific research questions around the 
following research themes: 
 Inequalities, diversity and social mobility 
 Early life antecedents of school readiness and later educational performance  
 Developmental origins of health and illness in childhood  
 Social, emotional and cognitive development: the interplay between infant and parent   
 Neighbourhoods and environment: effects on child and family  
Within each of these themes Life Study will explore cross-cutting issues, such as preterm 
birth or diverse families, and reflect contemporary UK population intergenerational 
influences on health and social outcomes. The cohort offers an opportunity to develop and 
test theoretical understanding of social and biological mechanisms operating through the 
life course, and to identify translational opportunities which might have early impact in 
relation to health and social policy. 
Previous UK cohort studies have demonstrated that parental background is a major 
influence on children’s development during pregnancy and infancy due to effects on 
maternal health, behaviour and parenting style as well as the social and material 
environment. A new scientific challenge is to capture the important inter- and intra-
generational influences on child development in 21st century UK. New perspectives must be 
sensitive to social diversity and the pace of social change and capitalise on advances in life 
 Page | 9  
 
sciences that help to clarify how biology and environment combine to influence 
development, health and well-being across the life course. 
1.4.1 Continuity with previous cohorts 
To investigate environmental and epigenetic influences on health, it is necessary to pool 
high quality data collaboratively with other cohorts and biobanks. To facilitate this, where 
appropriate, Life Study data collection protocols (including questionnaires) have been 
designed to be ‘compatible’ with their equivalents in other studies where appropriate.  
1.4.2 Sample size 
The proposed sample size for Life Study is much larger than previous longitudinal cohort 
studies and includes more than 60,000 pregnant women their babies and partners to be 
recruited through maternity units (Pregnancy Component) and 20,000 mothers, their babies 
and partners to be recruited after birth through national birth registrations (Birth 
Component).  
The sample size for the Pregnancy Component will provide sufficient power to enable 
reliable detection of moderately strong aetiological effects (e.g. relative risk ≥1.5) associated 
with risk factors (environmental, psychosocial, genetic) that are moderately common (e.g. 
prevalence ≥ 10%) on outcomes that are other than rare (e.g. prevalence ≥0.5%). The 
sample size of 20,000 births for the national probability component is based on a detailed 
technical report on sampling for the Millennium Cohort Study (MCS)3, and 
recommendations of the Longview Report4. A sample size of 20,000 maintains continuity 
with the Millennium Cohort Study and offers similar statistical power. The data from the 
Pregnancy and Birth Components will be integrated into a single dataset. Full details of the 
sample size calculations are presented in Appendix 3 
1.5 Participants 
The focus of this first funded phase of Life Study is the child in pre- and postnatal life. 
Initially, pregnant women in up to four urban areas of the UK will be invited to attend a Life 
Study Centre in the last five months of their pregnancy. At this visit, they will be asked to 
consent to their own participation in the study. When they attend the Life Study Centre on a 
second occasion when their baby is six months old, mothers (or the child’s legal guardian) 
                                               
3
 The Millennium Cohort: Technical Report on Sampling 4
th
 edition July 2007 edited by Ian Plewis; Centre for 
Longitudinal Studies ISBN 1 898453 62 4 
http://www.cls.ioe.ac.uk/studies.asp?section=00010002000100050004 
4
 (iii) Options for the Design of the 2012 Birth Cohort Study, 2009 available for download from 
http://www.slls.org.uk/#!longview-reports/c8a5.  
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will give consent to their baby’s long-term involvement in the study. Children will have the 
opportunity to provide their own consent to continuing participation, as they grow older.  
The mother’s partner will also be invited to take part in Life Study. In most cases, this will be 
the biological father of the child (defined by the mother), however, where relevant, same-
sex partners and non-biological parents or carers will also be encouraged to join. 
Information collected from non-biological parents or carers will enable examination of 
genetic and non-genetic intergenerational factors influencing child outcomes. The wider 
family of the child may eventually be invited to contribute data to Life Study but no contacts 
are envisaged in this first stage of Life Study. 
1.6 Timeframe 
The preparatory phase and pilot phases of Life Study were completed in December 2013.  
From January 2014, Life Study moved into its initial main phase which is referred to as Phase 
1. Recruitment to Phase 1 will commence in late 2014 and will continue until mid-2016 
when experience will be evaluated and plans for recruitment in Phase 2, currently 
anticipated to run until 2018, will be finalised. Currently it is anticipated that two centres 
will open in 2014 and the remaining two in 2016. Phase 1 will continue until October 2017 
to allow all follow up visits until 12 months of age to be completed.  
1.7 Funding 
Core funding: Life Study is funded through the UK Government Department of Business 
Innovation and Skills (BIS) Large Facilities Capital Fund (LFCF), the Economic and Social 
Research Council (ESRC), Medical Research Council (MRC) and University College London 
(UCL). Life Study forms part of the Birth Cohort Facilities (BCF) Project. Life Study is subject 
to the Office of Government Commerce (OGC) Gateway Review Process and Gateway 
Reviews 4a and 4b occur prior to Phase 1 and Phase 2 respectively. 
Enhancement funding: The Life Study Infection and Immunity Enhancement is being funded 
by a Wellcome Trust Strategic Award to UCL (Grant ref: WT101169AIA). Funding was also 
awarded by the Nuffield Foundation and the ESRC in March 2015 for development work 
and, subsequently, for an enhancement to Life Study to augment recruitment of non-
resident fathers and resident fathers/partners (Nuffield Foundation grants ref: CPF/41196 
and KID42046). 
NIHR CRN Portfolio: Life Study is registered on the National Institute for Health Research 
(NIHR) Clinical Research Network (CRN) portfolio (ref: UKCRN ID 15560; LCRN CSP 109744). 
This provides access to support for NHS Trusts supporting the recruitment of mothers in 
pregnancy.  
 Page | 11  
 
1.8 Research Ethics and Governance Approvals 
Life Study has undergone full ethical review by the Health Research Authority (HRA) 
appointed London-City & East Research Ethics Committee (REC). Members of the REC 
approved Life Study on 22nd January 2013 (ref: 12/LO/1492) with subsequent amendments 
submitted to reflect the evolving protocol over the preparatory, pilot and innovation (Phase 
1) phases for the Pregnancy and Birth Components. Approval has also been sought 
successfully from the HRA Confidentiality Advisory Group (CAG) under Section 251 (NHS Act 
2006) for the proposed initial contact and recruitment methods (ref: ECC 5-05(b)/2012). 
Life Study has been registered under the Data Protection Act 1998 as a UCL study (ref: 
Z6364106/2012/08/14) and the Information Commissioner’s Office (ICO) was provided with 
details of Life Study in March 2013.  
1.9 Organisational structures 
1.9.1 The Life Study Scientific Director and Team 
The Scientific Director of Life Study, Professor Carol Dezateux, is also the Life Study Principal 
Investigator (PI). She is based at UCL Institute of Child Health and is responsible for overall 
delivery of the project and overall scientific direction of the protocol. The Life Study team is 
based at the UCL Institute of Child Health and includes relevant expertise in clinical 
research, business operations, project management, information systems, communications 
and public engagement.  The Life Study Executive meets weekly and comprises the Scientific 
Director; the Deputy and Associate Directors - Professors Elias and Brocklehurst 
respectively; the Chief Operating Officer Anne Carey, the Chief Scientific Officer Dr Debbie 
Colson; and the Life Study Finance Officer Jack Foster. 
1.9.2 Governance structure and Committees 
The Life Study committees, their roles and responsibilities are outlined below (see also 
Figure 1).  
Corporate Board: Responsible for strategic decisions and accountable for funding. 
Management Board: All funding bodies are represented at a senior level with decision-
making authority. 
Project Board: Led from UCL and including membership from the Population Sciences 
Faculty, and UCL Finance, Procurement, IT, Human Resources and Facilities divisions; 
accountable for the project with the authority to direct the project within the remit set by 
Management Board 
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Life Study Strategic Advisory Committee (LSSAC): Provides independent assurance to the 
Management and Corporate Boards; Advises and challenges on strategic development and 
delivery. 
Scientific Steering Committee (SSC): Provides expert advice on scientific, strategic, 
operational and related issues; Agrees the overall strategic and scientific direction and 
objectives of the Project; Advises on strategy and policy development. Subgroups of the SSC 
have specific remits, such as managing applications for ‘enhancements’ to the scientific 
protocol; these will normally be externally funded. 
International Scientific Advisory Committee (ISAC): Acts as a scientific and strategic 
advisory committee; Advises on the scope of the scientific objectives and development of 
the resource to maximise its potential impact. Provides advice to the SSC and LSSAC. 
Figure 1: Life Study governance structures for the main phase (2014)  
 
1.10 Contacting Life Study 
  
Life Study 
Institute of Child Health 
University College London 
30 Guilford Street 
London 
United Kingdom 
WC1N 1EH 
Telephone: +44 (0) 20 7905 2137 
Fax: +44 (0) 20 7905 2381 
Email: info@lifestudy.ac.uk. 
Website: www.lifestudy.ac.uk 
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2 Life Study Scientific Protocol 
 
2.1 Study Design and sample size 
Life Study has been designed to achieve scale (numbers of participants) and depth (nature 
and extent of the information to be collected), thus providing data to inform important 
research areas relating to early childhood development. Life Study has an innovative design 
comprising two samples – a clustered Pregnancy Component and a nationally representative 
Birth Component.  See Appendix 2 for a summary Flow Diagram of the Study design. 
2.1.1 Pregnancy Component 
More than 60,000 pregnant women will be recruited through maternity units, with over-
representation of women from ethnic minority groups relative to the UK birth population as 
a whole and reflecting the population in which the Life Study will be located. The principles 
underlying the selection of the maternity units are outlined in Appendix 4. 
Mothers and partners will be invited to attend a Life Study Centre near their maternity unit 
on one occasion from the 20th week of pregnancy onwards, and again when their baby is six 
months and 12 months old.   
2.1.2 Birth Component 
The Birth Component will be a UK-wide sample of 20,000 births recruited using a clustered 
survey sampling design based on birth registrations and including approximately 16,000 
participants in England with the remainder drawn from Wales, Northern Ireland and 
Scotland.  
The Birth Component sample will allow inferences to be made from the data in the 
Pregnancy Component to the national population, facilitating comparability with earlier 
cohorts, and will allow researchers to explore possible biases in the Pregnancy Component 
sample when studying relationships between variables.  
2.1.3 An integrated dataset 
Integrating the Birth Component and Pregnancy Component will allow inferences to the 
national population, as well as exploration of possible biases in the Pregnancy Component 
sample. This requires that the two samples are recruited from births occurring within the 
same time period. The potential for secular trends also makes it essential that information 
from the Pregnancy Component sample can be anchored in information derived from a 
Birth Component sample that is contemporaneous.  
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The recruitment period is estimated to be four years, thus the cohort will consist of children 
with a 3-4 year difference in their ages.  This will be a very valuable resource to study 
childhood development and links with gene/environment expression. A spread of ages at 
follow-up can also be an advantage at certain transitions in the life course for quantitative 
traits, e.g. the analysis of growth patterns in infancy and early childhood and at puberty in 
adolescence. 
The Life Study design enables research findings to be placed within the context of a 
nationally representative population of very young children and will lay the foundation for a 
continuing longitudinal study of children born between 2014 and 2018. This will position the 
Life Study firmly within the UK’s powerful series of major birth cohort studies as the largest 
and most detailed birth cohort study ever conducted in the UK.  The Life Study will comprise 
a rich resource of longitudinal data and biological samples across all domains of relevance to 
the early years that will be used by a wide range of researchers to address research and 
policy questions from a life course perspective. 
2.1.4 Sample size 
Information collected from participants will contribute to a single integrated dataset of 
more than 80,000 mothers, their babies and partners, more than 200,000 participants in 
total. This sample size provides adequate statistical power to support robust analyses of the 
interplay between biology and environment. Details of the sample size estimates, proposed 
dataset integration and methodology for developing statistical weights are provided in 
Appendix 3. 
2.2 Development of the scientific protocol 
The draft scientific protocol was developed with input from clinicians, social and biomedical 
scientists and other relevant experts. The data collection instruments and measures were 
designed to reflect the scientific vision and key research themes, capitalise on the unique 
opportunities of this stage in the infant life course and to enable a wide range of policy 
issues relevant to children and health to be explored. The Scientific Steering Committee 
(SSC) maintained an overview of the process and was responsible for the final prioritisation 
of measures and instruments.  
Scientific Research Investigator Network Meeting: In November 2011, a two day meeting 
was attended by 40 members of the SRIN, which includes Life Study co-investigators, as well 
as additional experts from the social and biomedical sciences. Attendees identified and 
discussed the development of the protocol. 
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Review of other birth cohorts and longitudinal studies: The Life Study team reviewed 
previous longitudinal studies to inform protocol development, including identifying relevant 
instruments and opportunities for cross-cohort comparisons. 
Scientific Working Groups (SWGs): Six SWGs were established and co-chaired by social and 
biomedical scientists. SWG members identified and prioritised data collection instruments 
that could be included. A number of subgroups were also established, for example to 
consider mental health, and individual experts were also consulted. 
Scientific Protocol Development Group (SPDG): The SWG co-chairs together formed the 
SPDG which coordinated the integration of recommendations from the individual SWGs into 
a single draft protocol.  
Prioritisation of measures for inclusion: An initial prioritisation of the measures and 
instruments was undertaken by the SPDG in June 2012 and this was followed by a final 
prioritisation by the SSC in July 2012. External facilitators (Centre for Facilitation, CFF) 
assisted the prioritisation process.  
Public consultation on the scientific protocol: Public and expert consultation on the draft 
scientific protocol was achieved through a consultative conference (held on 17th July 2012; 
60-70 attendees; external facilitation by the Centre for Facilitation) and an independently 
conducted web-survey (TwoCan Associates, August 2012). 
2.2.1 Criteria for including instruments and measures 
The selection and prioritisation of data collection instruments was driven by clear criteria, 
including: 
 their potential scientific contribution to understanding the interplay between biology and 
the environment in shaping children’s (unequal) health and future wellbeing;  
 their reliability and public acceptability;  
 the opportunities for harmonisation with other national and international studies, including 
UK birth cohorts, to facilitate inter-study comparability; and  
 the obligation to minimise the burden on participants. 
2.2.2 Excluded instruments and questions 
Several measures were proposed but excluded after consultation. Criteria for excluding 
measures comprised measures that: 
 can be found elsewhere, for example the handheld maternity record, hospital 
obstetric notes or baby’s ‘Red Book’; 
 were regarded as potentially sensitive and more appropriate to a later visit when a 
participant has established greater commitment to the study, such as measures to 
identify ADHD and autism traits in the mother. 
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2.3 Data collection 
 
2.3.1 Pregnancy Component 
Pregnancy visit: Women, and their partners if they attend, will formally consent to take 
part, complete a questionnaire, be measured (height, weight and body fat), have eye tests, 
and provide blood and urine samples.  
Birth: Biological samples, for example saliva, urine, faeces and placenta will be obtained 
shortly around the time of birth from mothers who have previously consented to collection 
from them and their newborn babies. Any blood samples left over from the antenatal 
booking or screening tests or the baby’s newborn bloodspot screening (heel prick) test will 
also be collected and stored with the mother’s permission.  
Six and 12-month visits: Mothers (or parents) will complete questionnaires (including pre-or 
post-visit questionnaires) and their baby will have detailed measures of body size and 
neurodevelopment, including observations of maternal-infant interaction and eye tests. 
Samples of urine, faeces, saliva and oral fluid will be obtained from babies at 6 months 
(using non-invasive methods.), and again at 12 months. At the 12 month visit, samples of 
blood and urine will be requested from mothers. 
Additional information will be sought from the handheld maternity record that women carry 
throughout pregnancy, the mother’s hospital obstetric notes relating to pregnancy and 
birth, and from babies’ personal child health record (the PCHR or ‘Red Book’). 
2.3.2 Birth Component 
Six and 12 month visits: Birth Component participants (mothers, partner/fathers and 
babies) will be visited at home when the baby is six months old. The home interview will 
collect similar information as for the Pregnancy Component, but biological samples and 
physical measurements will not be collected. Information about the pregnancy and delivery 
will be collected retrospectively and a pre-visit questionnaire may be used. A further 
assessment using postal/web/telephone data collection methods will take place when the 
baby is 12 months of age.  
2.4 Recruitment 
The proposed pathways for recruitment in the main phase are outlined here. 
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2.4.1 Pregnancy Component 
All pregnant women who attend the 18-22 week fetal anomaly scan (described below as the 
20 week scan) within the participating maternity units will be invited to take part in Life 
Study. Women who book to deliver within a participating maternity unit will receive a flyer 
about Life Study at the time of their routine booking appointment or scan (around 8-16 
weeks of pregnancy and described below as booking). Women will be informed that they 
can notify their maternity unit staff if they do not wish to speak to research staff. Posters 
will be displayed in the maternity unit and will also highlight that the unit is participating in 
the study.  
Recruitment by research midwives (integrated NHS pathway): Where possible the 
participating maternity unit will employ practising midwives as part of the clinical care team 
who are also seconded to Life Study part-time. At the 20 week scan appointment, these 
midwives can provide pregnant women with information about Life Study and an invitation 
to participate. This model will be implemented and evaluated in the first Life Study Centres 
(Barking, Havering and Redbridge University Hospitals Trust, BHRUT and the University 
Hospitals of Leicester NHS Trust). Implementation in maternity units associated with future 
Life Study Centres will depend on local agreements. 
Recruitment by postal contact: Should the integrated NHS pathway not be possible in the 
remaining Life Study Centres and maternity units, women will be informed in a flyer that 
they will be sent an invitation to participate in Life Study, unless they indicate to the 
maternity staff that they wish to dissent from receiving any invitation. If women do not 
indicate that they wish to dissent, their contact details will be passed by the maternity unit 
to the central ‘mailing house’. The mailing house will be the Data Linkage and Extract 
Service (DLES), formerly called the Medical Research Information Service, which is based at 
the NHS Health and Social Care Information Centre (HSCIC). In line with approval obtained 
previously for Life Study5, DLES can act as a trusted third party (TTP) for personal 
information that is held prior to individual consent, and would send an invitation to 
participate in Life Study on behalf of the research team along with a letter of support from 
the local responsible obstetrician. Information about non-responders would be collected by 
DLES to evaluate and characterise response bias. This process is similar to that proposed for 
contact with the Birth Component as described below. 
See Appendix 5 for an outline of the recruitment pathway. 
                                               
5
 Life Study has obtained approval from the Health Research Authority Confidentiality Advisory Group (CAG) 
under Section 251 of the NHS Act 2006, for a mailing house to be operated by DLES, which operates to IG 
Toolkit and ISO27001 standards for information systems security. 
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2.4.2 Birth Component 
Recruitment by postal contact: Initial identification of babies eligible to be invited to 
participate in the Birth Component in Life Study will be through random sampling of new 
birth registrations across the UK. New births must be registered within six weeks (42 days) 
of birth. Staff at the Office for National Statistics (ONS) will randomly sample births in 
England and Wales (using a sampling frame defined by Life Study statisticians). A cross-
check against mother and baby’s data would be undertaken prior to mailout to ensure 
letters are not sent to households in which either the mother or baby has died.  
ONS staff will send the first letter of invitation on behalf of Life Study to the randomly 
selected mothers in England and Wales, and up to three reminder letters to non-responders 
at intervals of 2-3 weeks. ONS have previously sent mailouts on behalf of researchers. 
A similar approach to recruitment will be used in Scotland and Northern Ireland through the 
respective birth registration systems (National Records Scotland [NRS] and Northern Ireland 
Statistics and Research Agency [NISRA]). Appropriate approvals will be sought. 
See Appendix 5 for an outline of the recruitment pathway. 
2.5 Consent 
Pregnancy Component: Consent to take part in Life Study will be sought from mothers and 
partners at the Life Study Centre at the start of the pregnancy visit. Consent for biological 
samples to be taken from mother and baby at birth will also be taken at this visit to avoid 
consent being required during labour.  
Consent for the unborn baby to participate will initially be taken at the pregnancy visit so 
that the birth outcome and baby can be followed up to the second visit. At the second visit, 
when babies are around six months old, the mother or parent will reconfirm consent to the 
baby’s participation in Life Study. 
Birth Component: Consent to take part in Life Study will be sought from and for all 
participants at the home visit. 
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Table 1: Timing of consent in the Pregnancy Component  
Timing of request Consent from Consent for 
Pregnancy visit Mother First pregnancy visit; biological samples at all 
visits; routine record linkage; participation in 
Life Study; future contact. 
 Father/Partner First interview & visit; biological samples at the 
visit; routine record linkage; participation in 
Life Study; future contact. 
Unborn baby Mother (or 
parent/legal 
guardian) 
Biological samples at birth; routine record 
linkage; participation up to six months of age. 
Six month old infant Mother (or 
parent/legal 
guardian) 
Biological samples at 6 and 12 month visits; 
details of birth outcome; routine record 
linkage; participation in Life Study; future 
contact. 
 
2.5.1 Teenage mothers 
Although a child under the age of 16 years is below the legal age to consent, they are often 
considered to have the capacity to consent to their own healthcare treatment and 
interventions. They are also frequently asked to provide assent to participation in health 
research, when a parent or legal guardian has consented on their behalf. As mothers in Life 
Study are being asked to consent to participation long-term in research not only for 
themselves but also for their babies, we have sought advice from legal experts and 
concluded that pregnant girls or mothers under the age of 16 years will not be recruited to 
Life Study. The basis for this decision is outlined in more detail in the Life Study Ethics, 
Information Governance and Access Framework (available from www.lifestudy.ac.uk). 
2.5.2 Consent for the unborn baby 
Before birth, the unborn baby is not considered a legal entity and taking parental consent to 
long-term participation in Life Study could be contested. However an important principle is 
that seeking consent for the baby to be involved in the study should not be sought at birth, 
as this is likely to be a time when mothers may not be in a position to appropriately consider 
and give informed consent. At the pregnancy visit, consent will therefore be sought from 
mothers to obtain biological samples from the baby at birth6 and to undertake record 
                                               
6
 In studies of emergency neonatal care it has often been considered acceptable to seek consent before birth 
as parents are often better able to consider the decision in their own time and thus make an informed 
decision. 
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linkage to health-related records from birth. Consent for the baby to participate long-term 
in Life Study, for record linkage to education records and for the collection, long-term 
retention and use of samples, will be sought from the mother during the visit when babies 
are aged six months. 
2.6 Partners 
The child’s biological father, or the mother’s partner, are of key importance to the child’s 
early life development, through their genetic contribution and/or influence on the caring 
environment that the child experiences. Consideration has been given to the method of first 
contact with partners as they are often excluded from longitudinal cohort studies. In the 
Pregnancy Component, research midwives will approach partners who attend the antenatal 
clinic and scans to provide them with information about the study and invite them to 
participate. If partners do not attend, each woman will be given an information pack 
(containing a covering letter and participant information sheet) for her partner. Women will 
be allowed to choose to whom they give the ‘partner’s pack’, this may be the child’s 
biological father or another partner who will help care for the baby. They may choose not to 
pass on the pack at all. When they confirm their appointment, pregnant women will be 
asked if they are willing to provide the name and relevant contact details of the partner to 
whom they have passed the information pack.  
Life Study also aims to collect partner’s contact details, dates of birth and NHS numbers 
from women at the time of the first contact or visit, to allow partners to be invited 
individually in their own right to be participants in the study. This will be undertaken with 
the woman’s permission and is considered unlikely to be disclosive as the partner’s details 
are usually provided as next of kin on the maternity record, and fathers are often named on 
the official birth registration. However, Life Study will have a procedure for registering any 
complaints that may arise from a woman providing her partner’s contact details and will 
address these appropriately. 
Partners may also directly contact or ‘register’ online with Life Study to confirm their 
interest in participating and provide contact details so they may be contacted directly in 
future. The acceptability of this approach to fathers and partners will also be tested with 
potential participants early in the recruitment phase. 
Partners/fathers may attend the Life Study Centre with the mother or at another convenient 
time. In the Birth Component, both the mother and her partner will be invited to be present 
at the home visit and every effort will be made to carry out interviews when both are 
present. 
 Page | 21  
 
The Life Study pilot, as well as experience from other cohort studies, suggests that partners 
may be less responsive to the invitation to take part than mothers and are also likely to 
favour different modes of data collection, for example e.g. post, web- or text-based. 
The Life Study Expert Advisory Group on Fathers and Partners was established to address 
the specific challenges and opportunities of including fathers/partners as participants, and 
to advise on a proposal to the Nuffield Foundation to augment the recruitment and 
retention of resident and non-resident fathers/partners in the Life Study in order to address 
two major aims: 
 Describe trajectories of resident and non-resident fatherhood/partnering from pregnancy 
and in early life; 
 
 Examine how a father/partner’s anticipated involvement in their child’s life as reported 
during pregnancy relates to their involvement after once the child is born. 
The additional funding awarded in March 2015 by the Nuffield Foundation for this project 
will permit augmented recruitment of non-resident fathers/partners, with a particular 
emphasis on the Birth Component, and on resident and non-resident fathers/partners newly 
identified by mothers following the birth of the child in the Pregnancy Component (including 
after a change in partner). In addition, retention of fathers/partners will be improved by 
offering at least one further contact (including different contact types, such as web- and 
telephone-based interviews) following recruitment and before the child’s first birthday and 
requesting consent to record linkage in those who have not previously provided this. 
2.7 Pregnancy Component: Life Study Centre Visit 
2.7.1 Invitation and appointment scheduling 
At the 20 week scan, pregnant women will be approached by the research midwife and 
given an invitation, participant information sheet and, if willing, a provisional appointment 
to attend their local Life Study Centre. Women may delay making an appointment and will 
be given full details of how to make or cancel an appointment. A double appointment for 
the woman and her partner will be arranged if both wish to participate and attend together. 
Contact to confirm an appointment will be through phoning (free of charge) or returning a 
reply paid card to the Life Study Centre which will then schedule appointments and ensure 
efficient use of the Life Study Centre. Text and web-based appointment confirmation or 
scheduling option will also be activated if feasible.  
2.7.2 Estimated Recruitment 
Duration of recruitment has been estimated using an estimated response rate of 50% in the 
Pregnancy Component. This estimate is based on other birth cohorts; MoBA recruited 35% 
of mothers approached in pregnancy, Born in Bradford 70% and ALSPAC an estimated 70%. 
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The Millennium Cohort Study (MCS), which contacted mothers after birth, achieved a 
response rate over 70%. Life Study recruitment will be monitored closely during the main 
fieldwork and the Study has been phased to enable recruitment methods in pregnancy to be 
tested and refined before opening the remaining Centres. Life Study will also develop a 
careful programme of local community engagement to encourage participation, solicit local 
views on the study (e.g. identifying local issues or concerns) and to inform local 
communities about the study. The Birth Component recruitment and retention will be 
tested and refined in a longitudinal pilot study. 
2.7.3 Pilot of the Pregnancy Component visits 
A pilot of the Life Study visit for the Pregnancy Component was undertaken from September 
2013 to November 2013 (approved under Life Study substantive amendment 2.0, dated 
10th September 2013). Life Study commissioned a fieldwork agency (NatCen Social 
Research) to undertake the pilot evaluation. The objectives of the pilot were to validate, test 
and operationalise the scientific protocol, including the questionnaires, interview and 
assessment schedules, instrumentation and standard operating procedures (SOPs).  
All four participant types (pregnant women, partners, 6 and 12 month old babies with their 
mothers) were included in the pilot but each participant was seen only once and there was 
no longitudinal follow-up or record linkage. The only biosamples taken were saliva and urine 
from infants to test the methods for collection. Mothers of 12 month old infants also wore 
an accelerometer over several days so that the instrumentation, feasibility of measurement 
and acceptability of these could be evaluated. The pilot recruited 41 participants, including 
26 pregnant women, 6 male partners, 4 mothers with babies aged 4-8 months and 5 
mothers with babies aged 10-14 months. A short report, highlighting potential lessons from 
the pilot for the final scientific protocol and main phase of Life Study, was provided to the 
SSC. The scientific protocol to be used in the main phase visits have been informed by 
results from the pilot feedback, which included the acceptability of different measures to 
participants.  
Life Study will utilise a Day 100 plan, in which the first 100 operating days of the first Life 
Study Centre will also be a period of phased implementation and focused evaluation of the 
study instruments and procedures to confirm these are acceptable to participants and that 
Life Study research data are being collected to the required quality and standard. 
2.7.4 Visit duration 
Data collection has been based on an average Life Study Centre visit of around 2 hours, 
including introduction and consent (15-20 minutes), questionnaires, interviews and physical 
measures and biological sampling (90 minutes), and a closing discussion with participants 
(10-15 minutes). The effect of fixed or flexible ordering of measurement stations and the 
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timings for each assessment were tested in the pilot and, where appropriate, compared 
with the original estimates. The inclusion, exclusion and revision of different questions were 
reviewed and final changes agreed by the SSC.  
2.7.5 Staff training 
Appropriately skilled staff will be trained to assess participants attending the Life Study 
Centres. Staff will have previous experience in health care, such as midwives, nurses, health 
care assistants and phlebotomists, and they will be employed jointly between the NHS and 
Life Study. They will be fully trained in their defined role for Life Study, for example in the 
pilot, interviewers with experience of undertaking home interviews in previous cohort 
studies were trained to undertake the physical measurements, while nurses undertook the 
biological sampling.  
2.7.6 Assessment stations 
Participants will move through a series of dedicated stations, including: 
 Interview 
 Self-complete computer questionnaire 
 Adult and infant anthropometry 
 Child development testing 
 Vision testing 
 Biological sampling. 
 
A proposed layout for these ‘stations’ in the Life Study Centres is provided in Figure 2.  The 
Centres will also include play and breastfeeding facilities.  
Figure 2: Proposed layout for Life Study Centres indicating different stations to be included* 
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*the layout omits the blood sampling room which may be located within the adjacent antenatal clinic or in the Centre 
depending on local arrangements. 
2.7.7 Accessibility 
Barriers to participation will be minimised for all participants. Participants who confirm an 
appointment will be asked about any specific requirements for language and access. 
Language and communication: Through liaison with maternity units, the main languages 
used by local mothers will be identified and written information translated into the relevant 
languages. Staff recruitment in Life Study Centres will take account of local language needs 
and interpreting facilities will be procured as required to support participants in languages 
other than English, including sign language. Questionnaires will be provided in an aural 
format for women who have visual or literacy difficulties. The participation of women with 
hearing difficulties will be supported through written materials or signing.  
Mobility issues: Life Study Centres will be selected to be suitable for a healthcare purpose 
and internally designed to be easily accessible to participants using wheelchairs or mobility 
devices, as well as for prams, buggies and pushchairs.  
Transport: The location of a centre will take account of transport links for women who 
attend the local maternity unit. 
2.7.8 Reimbursement of travel expenses 
Participants attending the Life Study Centre will be offered reimbursement of their travel 
expenses. In recognition that women may wish to have someone accompany them to help 
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out with children or look after them if they feel unwell, one accompanying individual will 
also be eligible for reimbursement of travel. At the end of each visit, expenses will be 
provided or an explanation given of how to claim these. 
2.7.9 Life Study Standard Operating Procedures and Policies 
Life Study Standard Operating Procedures for each stage of the visits for the Pregnancy 
Component were developed for the pilot and staff training was undertaken to support 
implementation of these. Feedback from the pilot included evaluation of the SOPs; some 
amendments have been made and they are now appropriate for use in the main phase.  
The Standard Operating Procedures are available as separate reports for download on the 
‘Resources’ page of the Life Study website www.lifestudy.ac.uk. 
Additional policies were also put in place for both the pregnancy and birth components, 
reflecting policies of the local NHS Trusts, the Fieldwork Agency or the Biorepository 
Provider responsible for employing and training staff delivering the Study. These included 
and which they were trained, including those relevant to Information Governance and Data 
Protection, Serious Adverse Events, Incident Management, Safeguarding, Health and Safety 
and Complaints Procedures.  
2.7.9.1 Health or safeguarding concerns 
As the Pregnancy Component is being carried out in NHS facilities and is recruiting NHS 
patients, should Centre staff have any clinical concerns about the results of any assessments 
during the visits, they will notify the Centre Manager in accordance with the written Life 
Study policy. Concerns will be discussed with the local Trust or area Safeguarding Team and 
advice sought. Life Study has developed and implemented a Safeguarding Policy and 
provided Level 1 Safeguarding training for staff involved in the Life Study pilot. This policy 
was adapted to meet any local requirements and implemented in all Life Study Centres.  
2.8 Life Study Questionnaires and Measurements  
2.8.1 Questionnaires and interviews 
2.8.1.1 Topic Groupings and High-level Topic Areas 
The information that will be collected through self-complete and interviewer-led 
questionnaires can be divided into three broad topic groupings and a set of higher-level 
topics are contained within each of these (Figure 3)  
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Figure 3: High-level topic areas 
 
Topics and question modules for the main phase questionnaire and interview schedules 
were agreed by the SSC (see Appendix 6).The Questionnaires for the pregnancy and birth 
components for all currently planned stages of Life Study are available from the ‘Resources’ 
page of the Life Study website.7 
2.8.2 Physical Measurements 
The physical measures to be performed at the assessment centre include: 
2.8.2.1 Anthropometry  
This term refers to the measurement of height, weight, body size and composition, and 
changes in these over time. Women will be measured in pregnancy and at 12 months, 
partners at the first visit and babies at both the 6 and 12 month visits. The measures 
undertaken in adults will include sitting and standing height, bioimpedance8 (body 
composition), weight, triceps and subscapular skinfold thickness (using Holtain calipers), and 
waist circumference. In babies, the measures will include length and weight, and 
                                               
7
 www.lifestudy.ac.uk  
8
 Bioimpedance has been previously used in pregnant women and is considered safe for mother or baby. The 
only exclusions are for those wearing pacemakers or with any prosthesis.  
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subscapular skinfold thickness (using Holtain calipers), mid-upper arm circumference and 
head circumference.  
2.8.2.2 Vision 
The vision tests will be undertaken in adults (at the pregnancy visit) and infants (when aged 
12 months). They include plusoptiX screening for malalignment of the eyes (squint), a Frisby 
stereovision assessment (as a test of neurocognitive function), and assessment of refractive 
error by measuring the glasses prescription (using a focimeter or transcription of the 
prescription). A digital photograph of the eyes will be taken if the plusoptiX screening tool 
cannot register both eyes. 
2.8.2.3 Child Development 
Eye-tracking (Gap Task): The baby’s visual attention will be assessed using the Tobii Eye 
Tracker at 6 and 12 months of age. Cameras will record the baby’s responses to a series of 
images on a screen. 
Child Development Assessments: The baby’s development will be assessed during a series 
of tasks performed with the mother (or caring adult) at the 6 and 12 month visits. These 
activities will be recorded using a digital camera and scored later against a scoring standard. 
The activities at 6 months will include mother-baby interaction. At 12 months, the tasks 
include restraint in a high chair, and a joint attention task.  
The Standard Operating Procedures for the anthropometry, vision and child development 
assessments for all currently planned stages of Life Study are available from the ‘Resources’ 
page of the Life Study website.9 
Table 2: Physical measures assessed in the pilot 
 Pregnancy visit 6 month visit 12 month visit 
 Mother Partner Mother Baby Mother Baby 
ANTHROPOMETRY  
Weight (Infant and Adult)       
Adult Bioimpedance (BIA)       
Adult height       
Infant length       
Adult sitting height       
                                               
9
 www.lifestudy.ac.uk  
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Adult waist circumference       
Skinfold thickness       
Infant head girth       
VISION  
Eye examination (plusoptiX)       
Photograph of eyes        
Stereovision (Frisby test)       
CHILD OBSERVATIONS  
Gap Task (eye-tracking)       
Restraint in high chair       
Mother-baby interaction       
Joint attention       
 
2.9 Biological Samples (Pregnancy Component) 
Biological samples will be collected, with consent, from Pregnancy Component participants 
only. At the Life Study Centre pregnancy and partner visits, blood, urine and saliva will be 
collected from the mothers and their partners. At the six and 12 month visits, urine and 
saliva will be collected from the babies. Samples will also be collected in hospitals at birth 
(see below).  
The collection of biological samples (biosamples) will be minimally invasive to cause as little 
distress as possible. Blood sampling will only be undertaken from adults and no blood tests 
are to be carried out on the infants. Blood samples will be taken by staff trained in 
phlebotomy.  
The newborn bloodspot (NBS) is routinely collected from all babies born in the UK at 5-8 
days of age and used to screen for a range of disorders (further details of the screening 
programme are available at: http://newbornbloodspot.screening.nhs.uk/). Residual 
bloodspots, ‘leftover’ after newborn screening has been completed, are stored for research 
and will be retrieved by Life Study to provide a source of infant blood. Cord blood will also 
be taken at birth when this is possible. 
2.9.1 Collection of biological samples at the Life Study Centre 
At their first visit to the Life Study Centre, mothers and partners will be asked to provide 
blood, urine and saliva samples (see Table 2). A sample of 40-50ml of blood (about 3 
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tablespoons) will be taken from each participant.10  Pregnant women will be prompted to 
bring their handheld maternity records to their first visit when consent will be sought for the 
collection of umbilical cord and other biological samples at birth (see Table 4).11 The 
mother’s consent for sample collection at birth will be recorded in her maternity record.  
At the 6 month visit: when a mother attends with her baby, samples of urine, faeces, oral 
fluid and saliva from the baby (but not blood) will be obtained. No samples will be taken 
from the mother at this visit. 
At the 12 month visit: mothers will be asked to provide an additional 40-50ml sample of 
blood, and a urine sample. Urine, stool (faecal sample), saliva and oral fluid samples will be 
sought from the baby.  
The collection of the biosamples listed in Table 3 was evaluated in infants in the pilot (Sept 
to Nov 2013, performed by NatCen Social Research on behalf of Life Study). A report of the 
Standard Operating Procedures for Biosamples is available from the ‘Resources’ page of the 
Life Study website.12 
 
Table 3: Biosamples collected from infants in the pilot 
Biosamples to be collected from Infants 6 month visit 12 month visit 
Infant urine – using cotton wool balls   
Infant saliva – using Oragene ‘sponge on 
stick’ kits 
  
 
2.9.2 Collection of biological samples at birth 
Women recruited to the Pregnancy Component will be booked to deliver in one of the 
participating maternity units and the collection of samples around the time of birth will be 
facilitated by this design.  Consent to collection of samples at birth will be taken at the Life 
Study Centre pregnancy visit and recorded clearly in the women’s maternity notes along 
with detailed instructions for the collection of samples. Midwives in collaborating maternity 
units will be briefed and trained to collect samples.  
                                               
10
 This sample was acceptable to participants in the UK Biobank study and is not greater than the sample taken 
from pregnant women attending the maternity unit at the time of booking. 
11
 These samples are viewed legally as ‘maternal waste’ products, therefore maternal consent can be given 
before birth. 
12
 www.lifestudy.ac.uk  
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Additional funding has been secured from the Wellcome Trust for an enhancement, which 
will allow additional samples to be collected around the time of birth to specifically 
investigate aspects of infection and immunity and the impact on later outcomes (including 
the role of the microbiome, PI: Professor P Brocklehurst, UCL Institute for Women’s Health 
and Associate Director of Life Study). A pilot to evaluate the feasibility of sample collection 
at birth and any sample processing requirements prior to long-term storage was carried out 
at UCLH in February 2014 (REC substantive amendment 3.0, approved 2nd Jan 2014). The 
results informed the final list of samples to be collected at birth in the main phase of Life 
Study. Table 4 summarises the biological samples to be requested and collected during visits 
and at birth. 
2.9.3 Processing and storage of biosamples 
The principles underlying the methods chosen for sample collection and processing are to: 
 Collect, process and store samples to serve as wide a range of scientific investigation as can 
be anticipated 
 Reject material for collection where a single measure will be too variable (e.g. salivary 
cortisol) or the molecule of interest can be measured in samples already included in the 
study 
 Avoid processing approaches that preclude some future analyses 
 Centralise and standardise processing methodology to ensure consistency and 
reproducibility, and reduce cost  
 Provide a broad, secure and consistent dataset on each participant sample through the use 
of automated, highly validated assays. 
Storage and processing of samples will take into account the assays that are anticipated to 
be the most likely to be undertaken in future, for example whole genome sequencing (see 
Table 5). In order to maintain biological sample quality and minimise degradation, samples 
will be stored in the most appropriate conditions feasible, and freeze/thaw cycles will be 
limited where possible. This is likely to include long-term storage in a biobank archive at 
ultra-low temperatures to ensure long-term stability and integrity, e.g. -80°C. In selecting 
the most appropriate mode of storage for biological samples, the anticipated demand for 
samples may be balanced against the costs of storage and the costs and expected error 
rates of sample retrieval. Back-up samples will be stored securely in a second geographical 
location. 
Table 4: Sample types to be obtained by setting, participant and sample type 
Setting 
Participant and 
timing 
Protocol type Sample type 
Life Study Centre Visit 
 Mother in pregnancy 
  Core Blood, Urine 
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(1) Saliva will only be collected from multiple births (twins etc) and babies for whom no placenta was 
collected, to provide a source of DNA. 
  
 Father/partner in pregnancy 
  Core Blood, Saliva, Urine  Blood/Saliva(1) Urine 
 Baby at 6 months 
  Core Urine, Saliva(1) 
  Enhancement Oral fluid, Faeces 
 Baby at 12 months (Phase 1 only) 
  Core Urine 
  Enhancement Oral fluid, Faeces 
 Mother at 12 months (Phase 1 only) 
  Core Blood, Urine 
NHS setting 
 Baby at birth 
  Core Placenta, Placental Membranes, Umbilical 
cord 
  Enhancement Cord blood, nasopharyngeal swab, Urine, 
Meconium/faeces,  
(including faecal and urine samples 
collected during the first two weeks of life 
by mother, midwife or health visitor and 
posted to Life Study) 
 Mother at delivery 
  Enhancement  Vaginal swab, Urine, Faeces 
 NHS left over 
samples 
Core Maternal antenatal screening serum, 
newborn screening dried blood spot  
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Table 5: Indicative analytes (i.e. samples stored for these purposes) 
Indicative analytes 
Genome and Epigenome 
• Whole genome/exome sequence: blood, placenta 
• Epigenetics – eg methylation: blood, placenta, saliva 
• *RNA, transcriptomics(1) 
 
‘Infectome’ and Immunity 
• Microbiome – vaginal and faecal mother, infant faecal 
• Infections – e.g. CMV, EBV, VZV antibodies and/or DNA:  cord blood, maternal blood, 
oral fluid 
• Immunology: immunophenotype: cord blood, parental blood, placenta 
• C reactive protein 
 
Metabolome including Endocrine and Biochemistry 
• metabolomics: urine, placenta, blood 
• Thyroid, parathyroid: maternal and infant blood 
• Plasma Calcium Phosphate and Alkaline Phosphatase - 
•  Lipids 
• HbA1C 
 
Exposome: Micronutrients and vitamins 
• Folate: maternal, infant blood     
• Iodine: maternal and infant urine  
• Vitamin D: Serum 25-hydroxyvitamin D and 1,25-hydroxyvitamin D3: maternal and 
infant blood 
 
Exposome: Pollutants  
• Tobacco products        
• Alcohol biomarkers 
• Trichloroacetic acid        
• Total urinary bisphenol A 
• Phthalate monoester metabolites 
• Hydroxypyrene 
• Organophosphate pesticides 
•  Heavy metals 
• Persistent organic pollutants 
(1) RNA will be collected in parental blood; RNA in infant is not included in the core sample collection   
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2.9.4 Analysis of biosamples 
Although indicative examples of analyses relevant to the research themes and hypotheses 
of Life Study are provided, assays will not be undertaken immediately after collection.13  
Expert opinion will be sought regarding the scientific opportunities and optimal use and 
maintenance of the biosample resource, taking into account the expected technology 
development curve. Specifically, advice will be sought about the timing of the analysis of 
samples collected in Life Study and implications of proceeding with or deferring analyses 
until the sample collection is complete across all relevant participants. Areas that are 
potentially of great importance for Life Study, but where the high-throughput technology is 
still developing, are exome and whole genome sequencing, epigenomics and the 
microbiome. The cost of these technologies is likely to fall significantly in future, and the 
requisites for the delivery of high quality will become better understood, so it may be 
prudent to wait until these technologies have matured before processing Life Study 
samples. The experience of UK Biobank - currently extracting DNA from samples as a 
prelude to genome wide analyses – will be very useful to Life Study.  
An important goal will be to generate derived non-depletable data, which could be made 
accessible to the research community as early as possible, however consideration will also 
be given to the retention of samples long term for future analyses that are as yet undefined. 
2.9.5 Access to biological samples 
Access to biological samples will be carefully considered to ensure maximal utility is made of 
a finite resource. A specified time to process and analyse data will be agreed and biological 
samples will be provided to approved investigators on a cost-recovery basis.  
The following principles for access will be observed: 
 All research on and access to samples, and data derived from samples, will be in keeping 
with the consent obtained and with Life Study ethics, governance and data access policies, 
as will publication of research results and data 
 All requests for access to biological samples for specific research proposals will be assessed 
by an Access Committee according to a pre-defined set of criteria.  
 Where specific assays are identified as essential for the delivery of the Life Study primary 
objectives, these will be given appropriate priority.  
 Data derived from assays will be deposited in the Life Study resource where appropriate. 
Unnecessary duplication of assays will be avoided.  
                                               
13
 These principles are similar to those underlying the development of the UK Biobank biosamples resource.  
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 Following approved requests for access to biological samples, assays may be organised by 
the Life Study scientific leadership team to ensure appropriate quality control and feedback 
of results.  
 It may be appropriate for samples to be analysed overseas, for example where the best 
laboratory to perform the analysis is based overseas or where the sample analysis is being 
carried out as part of an international collaboration.  
 Any commercial access to samples will be on condition that the results are returned to Life 
Study within a fixed time and the findings published in full in open access peer reviewed 
media.  
 Any samples left over after laboratory analysis is complete will be returned to Life Study 
where possible. 
2.10 Record linkage 
The main individual person-level record linkages14 for which consent will be sought in this 
first sweep are described here: 
 Primary care and hospital health records including visits to GPs, hospital admissions and 
attendance, records of specific conditions such as cancer or diabetes, and prescriptions;  
 Permissions to trace participants through health-related demographic registers and to ‘flag’ 
them against future migrations or death;  
 Assisted conception records held by the Human Fertilisation and Embryology Authority 
(HFEA): for those who have had medically-assisted conceptions 
 Benefits and employment records: administrative records on benefits, tax credits, 
employment support programmes, as well as earnings, pension contributions and 
employment histories 
 2011 Census data for participants and, if possible, their households  
 Education records including the National Pupil database (NPD) and the Pupil Level Annual 
Schools Census (PLASC) database, as well as further and higher education records 
 Mobile phone records: mobile phone operator records on mobile phone traffic, including 
timing and duration of calls, texts, and data transfer 
It will be important to link to a range of neighbourhood (postcode level) variables, such as 
deprivation scores (e.g. Index of Multiple Deprivation (IMD), Townsend and Carstairs 
indices), local unemployment rates and housing tenure. There will also be linking to 
environmental data at postcode level, for example to existing measures of air and water 
quality. Linkage to individual address level derived variables, for example to import data 
around housing exposures or interventions or finer level environmental exposures, is 
currently possible in Wales and may well extend across the UK. 
Additional opportunities for linkage to local commissioning datasets are being explored 
within the first Life Study Centre. 
                                               
14
 Equivalent linkages will be sought in England, Scotland, Wales and Northern Ireland 
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2.10.1 Consent to record (data) linkage 
Consent for record linkage will be sought at the initial pregnancy visit. The Life Study record 
linkage working group explored different models for consent with key academic 
stakeholders and data controllers, including representatives of government departments.  
The acceptability of record linkage was also evaluated through the consultative conference 
and public engagement activities, including focus groups, undertaken during the pilot phase 
of Life Study. Specifically, it was decided that linkage to Ministry of Justice and police 
records would not be part of the current data collection sweep.  
2.10.2 Processing, storage and access 
Life Study is developing the processes required to manage the anonymisation, storage and 
linkage of datasets. It is anticipated that Life Study will centrally manage the anonymisation 
of different kinds of data and assignment and management of identifiers.  
2.10.3 Wider record linkage collaborations 
Life Study is working closely with the UCL and Swansea University components of the Farr 
Institute of Health Informatics Research (a UK network of centres of excellence in health 
informatics, financed by an MRC led group of ten funders) and the ESRC funded 
Administrative Data Research Centres, which are facilitating record linkage to other routine 
and administrative records in England, Wales, Scotland and Northern Ireland.   
2.11 Birth Component Home Visit protocol 
The Life Study Centre visit protocol will be adapted for use as a home visit interview for the 
Birth Component, taking into account the need to ask about pregnancy and birth 
retrospectively. There will be no biological samples or biomedical measures in the Birth 
Component. Piloting for the Birth Component home visit will be undertaken prior to 
recruitment starting in 2015.  
2.12 Enhancements to the core protocol 
In addition to the core-funded scientific protocol, funding may be sought by research teams 
to undertake ‘enhancements’ to the core data collection to fulfill specific research 
objectives. These enhancements may involve all participants or a sub-sample of those 
participating. Although each Life Study Centre will operate a common protocol, 
enhancement studies may be implemented in a limited number of centres.  
Applications to enhance data collection for a specified purpose will be approved by a 
subgroup of the SSC as described in the ‘Life Study Enhancements Policy’ and this also 
includes review by the Life Study Strategic Advisory Committee (SAC). Proposals will be 
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considered against an agreed set of criteria that include considerations such as scientific 
rationale, impact on the core Life Study objectives and design, participant burden, 
feasibility, ethics and governance issues, and funding. Enhancements require additional 
funding and applications to funding bodies are likely to be necessary. A substantive 
amendment for any approved and funded enhancement study will be submitted to the 
Research Ethics Committee to seek approval for any research activities that are outside the 
scope of the main study ethics approval.  
The Infection and Immunity Enhancement (PI: Professor Peter Brocklehurst; Wellcome Trust 
funded) proposes to collect detailed information regarding the pregnancy and delivery from 
the maternity unit, together with biological samples (e.g. umbilical cord blood samples, 
vaginal and faecal microbiome) in order to contribute to the understanding of infection and 
immunity in the fetus and neonate. This was the first enhancement to be approved by Life 
Study SSC, SAC and the Research Ethics Committee and funded through a Strategic Award 
made on 26th April 2013. Pilot work started in February 2014 in preparation for inclusion in 
the main phase protocol.  
The Non-Resident Fathers and Resident Fathers/Partners Enhancement (CoPIs: Professors 
Carol Dezateux and Kathleen Kiernan; Nuffield Foundation and ESRC funded) proposes to 
augment recruitment and retention of fathers and partners. This was the second 
enhancement to be approved by Life Study SSC, SAC and the Research Ethics Committee 
and funding was awarded on 31st March 2015. 
2.13 Follow-up and future data collection after the first year  
It is intended that all parents and children participating in Life Study will be followed up at 
later ages with further questionnaires and biological samples. Future data collection sweeps 
could record changes to family circumstances, longitudinal growth and development, and 
evaluate key outcomes, such as neuropsychiatric conditions, vision, asthma, educational 
achievement and social identity.  Further follow up of participants would include linkage to 
relevant electronic records (see above), as well as web-enabled data collection (augmented 
by telephone, computer, or reply paid questionnaires) to maintain contact with children and 
families after the face-to-face centre and home visit(s). 
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3 Ethics, consent and confidentiality 
3.1 Ethical, Legal and Social Issues  
Ethical, legal and social issues can be complex and critical to the success of a contemporary 
large-scale epidemiological study. Rapid advances in biotechnology, information technology 
and the clinical and social sciences, and changes in societal expectations present a 
challenging array of ethical, legal and policy issues.  
Life Study will be the largest UK study of pregnant women and their partners and babies; it 
will collect information, biological samples for a biobank resource, and link to routine data 
explicitly from the outset. The study is likely to encounter a range of complex ethical issues 
that will not have been encountered in the previous national birth cohort studies, which did 
not recruit in pregnancy.  
Although external research ethics and governance approval processes ensure that the study 
design is ethically acceptable, Life Study requires mechanisms for adapting policies to 
address ethics issues arising over the lifetime of the study, and to respond to changes in the 
societal and legal context. Life Study will need to respond to specific issues, such as arise 
through public involvement activities or the implications of specific research findings. 
3.2 Life Study Ethics and Information Governance Framework  
A Life Study Ethics and Information Governance Framework15 has been developed to set out 
the Life Study approach to ensuring the ethical conduct of the study and management of 
the resource within the broad context of the Life Study relationship with participants, with 
research users, and with society.   
Issues considered in its development included: 
 Relevant activities/reports by other organisations, including Life Study funder policies; 
 Legal requirements relating to the management of Life Study information and samples;  
 Obtaining future-proofed consent for different types of data, including record linkage;  
 Obtaining consent from different types of participant, such as mothers, partners and babies 
(including consideration of mental capacity to give consent);  
 Children attaining capacity to consent during the timeframe of a longitudinal cohort study;  
 Feedback of incidental findings; 
 Recruitment and collection of information and samples from fathers and partners; 
                                               
15
 This is available as a separate report for download on the ‘Resources’ page of the Life Study website 
www.lifestudy.ac.uk.  
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 Principles of good information governance for participant information and biological 
samples collected, including the management of data security and access 
 Principles of access to the biological samples, which are a depletable resource 
 Commercial or international access to the data, or requests for access for non-research 
purposes e.g. related to issues of paternity. 
3.3 Life Study Advisory Group on Ethics  
A Life Study Advisory Group on Ethics has been established. See the Life Study Ethics and 
Information Governance Framework for more information.  
3.4 Key ethical concerns in the first ‘sweep’ of Life Study 
Two key ethical concerns have been addressed for the initial contact with participants are 
outlined below:  
3.4.1 Initial contact: Section 251 approval  
An important consideration for Life Study was the initial contact with pregnant women or 
mothers to tell them about the study and invite them to take part. Every woman who is 
eligible should have an opportunity to find out about the study and decide whether to take 
part, including women who are traditionally considered to be hard-to-reach, for example 
women who book or transfer late into a maternity unit, who do not understand English or 
have low literacy skills.  
As the Life Study design is intended to allow research findings to be placed within the 
context of a nationally representative population of very young children, it is vital to have 
information about the characteristics of non-responders to understand the potential for bias 
and to pro-actively recruit from under-represented groups. Anonymised or aggregated 
details (e.g. age, ethnicity) of all pregnant women or mothers are also needed to create the 
statistical weights to be used in analyses of the study data.  
Life Study successfully sought approval under Section 251 of the NHS Act 2006 for a ‘trusted 
third party’ to manage invitation mailouts (principally to the Birth Component sample) on 
behalf of Life Study, as well as to collate individual-level data from birth registrations to be 
used by Life Study ONS approved researchers for the analysis of non-response. 
 Feedback to participants3.4.2   
Providing health-related feedback within a research study has significant risks when tests 
are innovative, and test results may not be clinically relevant or readily interpretable with 
regard to the health implications for the individual. Participants will be clearly informed that 
Life Study is a research project and that they will not receive feedback or results from many 
of the novel tests undertaken during the visit.  
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4 Managing the Life Study Resource  
4.1 Information systems to manage appointments and the data resource 
Life Study will develop secure and robust Information Systems that can: 
 Capture and store data about participants throughout their involvement in the study 
 Capture data directly from participants 
 Manage flows of data to and from national institutions, e.g. ONS, UK Data Archive 
 Store and manage data for analysis and reporting. 
4.1.1 Key components of the system 
Participant Identification & Enrolment: The systems in use will begin by recording contact 
details and basic information from pregnant women and partners in maternity units, or 
babies and their families sampled through birth registrations. 
Midwives will use the Maternity Unit IT systems to identify eligible participants. Life Study 
Centres will be commissioned at accessible sites proximal to their ‘feeder’ maternity units.  
An appointment scheduling system will manage the scheduling of Life Study Centre 
appointments. This may be sited with the fieldwork or another agency. 
The Birth Registries are held by the Office for National Statistics (ONS) in England and 
Wales, the General Register Office for Scotland (GROS) and the Northern Ireland Statistic 
and Research Agency (NISRA).  
A Fieldwork Agency will be commissioned to manage contact details, appointment 
scheduling and home visits for the Birth Component.  
The Data Linkage and Extract Service (DLES) within the NHS Health and Social Care 
Information Centre may act as a trusted third party holding contact details held under 
Section 251 approval to inform list-cleaning and invitation mailouts for initial 
appointments.16 Key health status services that will support recruitment include the Patient 
Demographics Service (PDS) and NHS Numbers for Babies (NN4B; also sited within the PDS). 
Participant Record Management System: After consent, patient details will be held within a 
centralised record system to facilitate follow-up. 
                                               
16
 Section 251 permission was obtained for this, however in the final design NHS Trust systems were utilised by 
NHS-employed Life Study staff within each Centre to manage the contact details and mail outs. 
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Participant Data Collection:  Information systems will include direct collection of data at 
interview, from measurements taken during the Centre visit or through self-complete 
computer-assisted questionnaire (survey).  
Data collected through all sources, including the Life Study Centres and home visits, will be 
returned to a central Data Management System for analysis and reporting, prior to 
archiving for access by research users. The Biorepository and UK Data Archive represent the 
final archives for data, measures and biosamples collected through Life Study. 
4.1.2 Specific requirements 
Several important components were highlighted as important for inclusion in the final 
information system, following testing tested in the pilot study: 
 Consent management: While electronic consent forms would allow for the recording of 
cryptographically bound signatures that comply with UK and EU legal requirements, it was 
ultimately found simpler to comply with Research Ethics Committee requirements and to 
provide participants with a paper copy of this form. 
 Accessibility: Information systems will be accessible for users with disabilities and compliant 
with the Disability Discrimination Act. 
 Tracking the Centre visit: During each visit, the data, physical measurements and biosample 
collections will be tracked effectively and associated with the correct participant records.  
 Survey management: All measures used for Life Study will be described within a metadata 
catalogue, which will be available to the research community for reference in support of any 
data access requests or protocol review.  
 Biosample management: All biological samples will be tracked and recorded from point of 
collection to the Life Study biorepository to comply with the Human Tissue Act. 
 Asset management: Study instrumentation, computer hardware, peripherals and software 
will be recorded in an asset register to support workflow (e.g. calibration reminders and 
fault handling).  
 Real-time dashboards: A central management dashboard will allow the study team to 
examine performance indicators in near real-time, and to identify unexpected issues in 
operational aspects of the study.  
4.1.3 Security standards and governance procedures 
Security of personal data is vital to Life Study. Life Study Information Systems will have 
different security zones with different requirements for information security depending on 
the nature of the data being collected or held. Handling of non-aggregated personal 
datasets will be contained within security zones that comply with best practice information 
security, independently assured to meet the ISO 27001:2005 information security 
management systems (ISMS) standard, compliant with the NHS Information Governance 
Toolkit and assessed as IL2 (Business Impact Level risk assessment). User and role based 
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access control will ensure that only personnel who require access to specified files and 
datasets are granted permission.  Data transfer will be in an encrypted format using AES256 
encryption standards. As necessary, additional security zones will be introduced, e.g. for 
fieldwork agency and biorepository services.   
4.2 Expectations of the Life Study resource 
Management of the resource must respect the undertakings to participants and funders, the 
principles contained in relevant Life Study policies, and the anticipated expectations of 
participants, researchers, funders and society:  
 Participants will expect a high degree of data security and confidentiality around sensitive or 
personal data and samples, and the resource to be managed in a way that is consistent with 
the participant consent and regulatory ethics approvals;  
 Researchers will expect data to be of high quality, up to date, validated and as complete as 
possible. Data should be accessible and useable; 
 Funders will expect high quality data to be made available as early as feasible, with as few 
restrictions as possible, and maximising the value of the data for research and for public 
benefit  
 Society will expect research data and samples to be used for the public good, confidentiality 
to be respected, proportionate governance, and for data and samples to be kept secure, 
safeguarding them for future use.  
 Public bodies such as the National Research Ethics Service, the Confidentiality Advisory 
Group of the Health Research, and the Human Fertilisation and Embryology Authority, will 
expect Life Study to meet certain standards; and obey relevant laws such as the Human 
tissue Act and Data Protection Act. 
4.3 Data Types 
The types of data and the principles for their storage and access outlined here:  
 ‘Questionnaire’ data from participants (including self-complete questions and interviews) 
 Biomedical physical measurement data, for example anthropometric and vision 
measurements collected at the Life Study Centre visit 
 Biological samples, such as blood, urine and placenta 
 Paradata, i.e. data concerning the process of collection of information or samples from 
individual participants 
 Metadata, i.e. catalogue data on the questionnaire instruments or biomedical assessments 
chosen, or on the collection and storage requirements for biological samples 
 Linked data, for example routine health and other administrative data obtained through 
record (data) linkage 
 New secondary data or derived variables, for example data derived from statistical analysis 
of Life Study data or from assays on biological samples.  
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Table 6: Time points for data and sample collection 
Visits Pregnancy Baby aged six months Baby aged twelve 
months 
Birth  
Component 
None 
Home visit  Web / postal / phone 
questionnaire  
 Questionnaire data 
from mother and 
partner/father 
 Retrospective 
pregnancy data 
 No biomedical 
assessments or 
biological samples. 
 No biological 
samples. 
Pregnancy 
Componen
t 
Life Study Centre visit 
by mother and 
father/partner 
Life Study Centre visit 
by mother and baby 
Life Study Centre visit 
by mother and baby 
 Questionnaire data 
 Physical/biomedical 
measures  
 Biological samples. 
 Questionnaire data 
 Physical/biomedical 
measures  
 Biological samples. 
 Questionnaire data 
 Physical/biomedical 
measures  
 Biological samples. 
Birth (hospital)   
 Biological samples.   
 
4.3.1 Disclosure risk 
Care will be taken to safeguard against any disclosure of personal data or breach of 
confidentiality of participants in Life Study.  The storage location, security safeguards and 
arrangements for access will vary according to the level of disclosive risk associated with 
different data types: 
 Non-disclosive and non-sensitive data (including in combination): these have a (very) low 
risk of disclosure will be deposited with the UK Data Archive and available to researchers for 
download after on-line user registration. 
 Moderately disclosive or sensitive data (e.g. postcodes): require a special license for access. 
Additional steps to remove/pseudonymise identifiers may be required.  
 Biological samples and data that are disclosive or sensitive (including some paradata): 
accessed via a specially constituted Data Access Committee applying an agreed set of criteria 
for the assessment of access applications. 
4.3.2 Usability of data 
Processing of data for access by researchers will depend on the usability of data. Broadly, 
Life Study data will include data that:  
 Page | 43  
 
 are useable by researchers with a minimum of processing (this minimum might include 
cleaning and anonymisation before wider distribution together with sample weights);  
 require additional (often expert) processing to produce useable data variables that can be 
incorporated in or otherwise linked to the existing Life Study database. This processing may 
involve data manipulation to produce derived summary variables from data collected 
directly in the Study (e.g. of socio-economic status or educational qualifications), or from 
more complex coded data collected initially through record linkage (e.g. Hospital Episode 
System data);  
 are produced from laboratory analysis of materials such as biological samples and which 
may require further processing of variable complexity to become useable.  
4.4 Storage of data and samples 
Arrangements for data deposits or storage will be appropriate to the sensitivity and 
disclosive risk associated with the data. Different archives will be selected as appropriate to 
the sensitivity of the data, for example: 
 Non-disclosive and non-sensitive data will be deposited with the UK Data Archive.  
 Moderately/highly disclosive or sensitive data will be deposited in a secure data 
archive. 
 Large and complex datasets, such as derived from genome-sequencing, may require 
specialised facilities, such as a repository for bioinformatics data. 
 Biological samples will be stored in a secure biobank (biorepository) with a back-up 
held at a separate geographical location. 
Data may be stored in separate locations or in one physical store but with different data-
handling protocols. Data extracts would be produced to service different classes of request. 
Data will also be stored in a geographically separate secure back-up location. 
4.4.1 UK Data Archive 
The UK Data Service hosts an archive containing key national and international survey data 
collections, international databanks, census data and qualitative data. It provides secure 
access to data of high sensitivity. The majority of data are fully anonymised and while 
accessible to researchers are not publicly accessible. Several types of data are deposited in 
this archive and made available including quantitative, qualitative, and multimedia data as 
well as non-digital material (See http://ukdataservice.ac.uk/get-data/about.aspx). 
4.5 Data Release 
By mid-2016, should recruitment attain the estimated 50% on which these figures are 
modelled, Life Study will have recruited up to 16,000 pregnant mothers, 11,000 
fathers/partners, and  -  c 16,000 babies - into the Pregnancy Component and – depending 
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on the outcome of the longitudinal pilot of the opt-in sampling strategy - up to 10,000 
mothers with babies into the Birth Component. It is anticipated that a single dataset from 
Phase 1 (pregnancy and six months data) will be released with sample weights in early 2017, 
following data cleaning and annotation. 
User engagement is essential to prepare and support data users so in preparation for the 
release of this integrated Phase 1 dataset, a ‘beta test’ dataset will be released together 
with descriptive metadata to enable researchers to familiarise themselves with the Life 
Study data variables and study design. A process will be developed for determining the 
appropriate timing and content of such datasets and the materials, training and 
communications necessary to prepare the scientific community for their release.  An 
additional consideration relates to the completeness of Life Study datasets in terms of the 
proportion of the participants recruited and the completeness of their follow up in any given 
data release. For example, if data collected in a subset of Life Study participants are released 
before all participants have been recruited across the country, any constraints on using data 
that specifically relate to that subset need to be fully understood and addressed. The 
frequency of subsequent data release remains to be determined and will ensure as early 
and complete access to the data for the research community as feasible.  
4.5.1 Questionnaire and biomedical assessment data 
Questionnaire data and some biomedical data will be released into the UK Data Archive, to 
be made available to users on an appropriate basis, with licensed access for sensitive or 
disclosive data.  
4.5.2 Large-scale data and bioinformatics 
Some types of biological sample analyses, such as genome sequencing, will create large 
volumes of complex data, which will require further analyses to provide meaningful 
variables for release. The storage of such data may be best managed through a 
bioinformatics resource. These data will need to be linked to the core Life Study datasets 
held at the UK Data Archive and will need additional work to ensure they are accessible to 
users.   
4.6 Data access policies and practice 
Life Study will be building on the UK’s established infrastructure for access to birth cohort 
and other longitudinal data resources, which ensures that appropriate safeguards are in 
place to minimise risk of disclosure and to respect the consent and preserve the 
confidentiality of participants.  
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In 2008, the World Health Organization and the Wellcome Trust initiated discussions around 
a common Code of Conduct on the sharing of data of public health importance. In 2010 this 
code was revised at Foggy Bottom and in 2011 the major research funders put out a joint 
statement on sharing research data to improve public health (signatories include the 
Wellcome Trust, ESRC and MRC).  
More recently the Expert Advisory Group on Data Access (EAGDA) was established by the 
Wellcome Trust, MRC, ESRC and CRUK to provide strategic advice on the emerging scientific, 
legal and ethical issues associated with data access for human genetics research and cohort 
studies. EAGDA is considering data access committees and incentives for data sharing, and 
has recently developed a statement for EAGDA funders on the risk of re-identification of 
anonymised research participants from genomic and other data. 
Some data from the biomedical measures, including videos of mother and child interaction, 
may require special access arrangements as the identity of mother and child cannot be 
masked. 
4.7 Framework for Managing, Sharing and Accessing the Data Resource 
4.7.1 Introduction 
A preliminary Life Study Data Access Policy was developed in 2012. A draft framework for 
managing, sharing and accessing the Life Study data resource is currently being developed; 
the Data Access Policy will be revised as required. The framework and policy set out a 
number of principles and undertakings relevant to data access. 
4.7.2 General principles for the management of participant data and samples  
The Data Access Policy will be based on the following draft principles: 
 The principles for access to LS data and biological samples, including any consideration of 
protected or preferential access, will take into account the three key principles identified by 
funders in the Foggy Bottom agreement, namely that access to the data and biological 
samples will be equitable, ethical and efficient17 
 Life Study data will be made available using the ‘intelligent openness’18 principles to inform 
the delivery of the Life Study datasets to users 
 The level of scrutiny used to assess applications will be proportionate to the nature and scale 
of the research project, taking into account the depletable nature of biosamples, any 
                                               
17
http://www.wellcome.ac.uk/About-us/Policy/Spotlight-issues/Data-sharing/Public-health-and-
epidemiology/WTDV030690.htm 
18
 Royal Society report ‘Science as an Open Enterprise’ 
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proposed contact with Life Study participants, potential implications for Life Study 
resources, and any ethics or other potentially contentious issues. 
 A legally binding agreement will be required in certain instances, for example for access to 
sensitive and disclosive data or biological samples. 
 Only members of the Life Study team will be allowed to contact study participants directly; 
strict guidelines regulating such contact will be required. 
 Anyone given access to the resource must undertake not to try to identify individual 
participants, or compromise the security of the data or the anonymity of participants. 
 Access to Life Study biomedical samples will be carefully considered to ensure maximal 
utility is made of a depletable resource.  
 Approaches to access Life Study data and samples should build on existing practice and 
reduce unnecessary duplication and competition. All information derived from Life Study 
data and/or samples (including any secondary or derived data) must be submitted to the Life 
Study team for inclusion in the Life Study central database.  
 There will be no onward sale of Life Study data or samples. All information derived from 
access to the Life Study resource (including derived variables and data derived from 
statistical analysis) must be submitted to the Life Study team for inclusion in the Life Study 
database. There will be accompanying documentation sufficient to identify the analyses 
undertaken and interpretation of the results, and a brief description of the methods used.  
 Under the current funding arrangements for Life Study, researchers given access to 
biological samples or modified datasets will be expected to meet all of the associated costs.  
 All users of Life Study data and/or samples must appropriately acknowledge the original 
study in their reported and published findings. 
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5 Communications, engagement and participant and public 
involvement  
5.1 Importance of Participant and Public Involvement (PPI) 
Communications, engagement, and especially participant and public involvement (PPI), are 
recognised as crucial to the success of Life Study. Participants – children and families – are 
at the heart of the study and key to delivering a study of this scope and ambition.  With this 
in mind, a dedicated strategy has been developed and is being implemented across the 
study to ensure a robust approach to communications, engagement and PPI. The Life Study 
Communications and Engagement Strategy has been published as a separate document and 
can be downloaded from the ‘Resources’ page on the Life Study website.19  The main 
elements of this Strategy are summarised in this section. 
The key audiences targeted by the Strategy are:  
 Participant audiences (including potential participants, families of potential participants, 
peers/friends of potential participants) 
 Healthcare professionals (including hospital trust leadership, maternity unit staff, 
community healthcare providers, GPs) 
 Researchers and academia (including other cohorts, scientific committee members, NHS 
research networks, educators) 
 Funders 
 Policymakers and political influencers (including Chief Scientific Advisor, Council for Science 
and Technology, ministers and officials in government departments with a major interest in 
Life Study, MPs, select committees, regional government and local authorities, local 
overview and scrutiny committees, think tanks) 
 Media (including local and national mainstream media, targeted and trade media) 
 Data services (including UK data archive) 
 Third sector (voluntary, not-for-profit and community groups) 
 Businesses (such as those marketing maternity and baby clothes, toys etc) 
 Life Study providers (such as fieldwork agencies and business analysts) 
 and the general public. 
5.1.1 Participant audiences 
Participant audiences require a distinct approach compared to the other target audiences as 
communications activities seek to aid recruitment and retention, and engender a sense of 
ownership of the study rather than just increase awareness of and support for the study. 
Developing a positive image for Life Study amongst potential study participants is a primary 
                                               
19
 www.lifestudy.ac.uk  
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objective for the first phase of the study. In later phases, communications activities will be 
focused on information provision to secure continued participation and maintain participant 
engagement.  Therefore, the approach is underpinned by four strategic principles that 
ensure that, whilst being flexible and responsive to diverse audiences, all elements of 
communications, engagement and PPI can be consistently and holistically delivered to meet 
participant needs and the key study objectives of recruitment and retention. 
5.2 Communications, engagement and PPI strategic principles 
5.2.1 Audience Led 
All communications are audience-led and, wherever possible, evidence-based; this audience 
focus extends into all aspects of study design. Life Study’s strategic approach is grounded in 
understanding our audiences and then tailoring communications to respond to those 
audiences’ specific interests, needs and concerns. 
Life Study has already been implementing a range of PPI opportunities that focus on both 
our communications as well as obtaining audience feedback on the study design. Research 
with audiences is undertaken formally (that is, as a structured programme of qualitative 
audience research) and informally (such as informal ‘soundings’ with key representatives 
from target audiences). Dedicated PPI groups will be an ongoing resource to support 
involvement (see ‘Next steps in PPI’). 
Examples of work being done to develop audience-led communications and embed 
evidence from PPI in other aspects of the study design include: 
 crafting messages based on audience research and PPI activity, rather than on internal Life 
Study views 
 using specific examples of potential research topics and findings to demonstrate value of the 
study to participants, as requested by focus groups 
 refining study questionnaires in line with specific feedback through focus groups and the 
study pilot 
 designing the facilities at Life Study Centres based on participant requirements 
 using communications channels that are already used and trusted by target audiences, 
including online 
 testing public-facing materials with participant audiences and members of the public to 
establish that they are fit-for-purpose, accessible and will achieve maximum impact. 
5.2.2 Phased 
Life Study audiences are taken on a journey that supports full understanding, commitment 
and participation.  It is important that Life Study ensures participants are given the 
opportunity to fully understand what they are committing to in Life Study. That is why 
communications and engagement activities will be approached in a phased way, creating 
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audience journeys that introduce layers of complex information so as not to overwhelm 
participants.  Examples of strategic phasing include: 
 developing audience messages to take them on a journey to participation and/or 
commitment – for example, using multiple formats for communicating (leaflets, postcards, 
online) and presenting different pieces of communication to participants at different times 
 concentrating communications on key study objectives (recruitment, data-sharing) at 
different points in the study 
 concentrating on milestones in parents’ and babies lives and understanding the importance 
of this special time. 
5.2.3 Building Trust  
Trust is the foundation upon which all other communications asks are made and imperative 
to participation in the study.  The building and maintenance of trust is relevant to all 
audiences and the foremost communications task throughout all phases of Life Study. 
Examples of how we are already working to build trust with our audiences, especially 
potential participants and the public include: 
 seeking and displaying endorsement from organisations and brands recognised and trusted 
by potential participants (for example, NHS Trusts with which we have been working) 
 up-to-date provision of accurate information – progressing plans to update our Life Study 
website 
 recognising the complexity of Life Study, using face-to-face communications where possible  
 tone – speaking to all supporters and participants in language that places them on an equal 
status.  No hyperbole or jargon.  Communications are pitched at a level that the majority can 
understand 
 thanking every participant and supporter properly, such as through the thank you letters 
following the pilot study. 
5.2.4 Inclusiveness 
Life Study wants to be representative of the rich mix of people living in the UK today.  This 
means that Life Study’s communications and other aspects of the study design must not 
exclude any potential participants or supporters.   
Examples of how we are already aiming to be inclusive include: 
 PPI work to understand the needs of participants and the public and making sure that 
materials and study design are responsive to those needs 
 Imagery showing a diversity of ages, ethnicities and family units 
 Language – for example, use of ‘partners’ and not ‘husbands’ 
 Using a guide reading age of around 12 years for all participant communications 
 Planning for provision of interpretation and translation services. 
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5.3 Engagement and PPI activities to date 
The initial PPI activities focussed on the pregnancy component. 
5.3.1 Focus group meetings to support Life Study branding exercise 
An initial consultation in March 2012 sought public feedback on the newly created study 
name, brand and logo. The Life Study communications manager field-tested three different 
visual designs in focus group meetings held in London and Birmingham20 with the study’s 
primary target audiences: pregnant women and their partners. It was considered critical to 
have input from the study’s target audience both from within and outside of London – with 
a mixture of women and men from different ethnic and social backgrounds. These focus 
group discussions provided validation for the study name, look and feel.  
Another important outcome of this consultation was the development of a working 
relationship with the Avon Longitudinal Study of Parents and Children (ALSPAC) young 
peoples’ group, who were also asked to provide views on the branding. This relationship will 
facilitate the development of similar participant involvement initiatives for Life Study.  
5.3.2 Lay representation on the Record Linkage Scientific Working Group 
There is a lay representative (parent) member of the scientific working group that is 
deliberating the approaches and timing being proposed for consent to data linkage within 
the Life Study cohort. Consideration has been given to information provision to participants, 
the appropriate wording of consent statements and the need for regular review. 
5.3.3 Ongoing public involvement representation on the LSSAC 
Within the Life Study governance structure the Life Study Strategic Advisory Committee 
(LSSAC) is responsible for providing independent assurance that Life Study is delivering 
against its core objectives.  The LSSAC directly advises on, and challenges, the strategic 
development and delivery of the project, advising the funders on key areas where they 
facilitate the effective delivery of the project. 
The membership of the LSSAC includes provision for two lay representatives with relevant 
expertise in the involvement of parents, children and young people in research, and they are 
able to advocate on behalf of participants in the study on an ongoing basis. As an example, 
the LSSAC and lay members were involved in making recommendations regarding the 
overarching communications, engagement and PPI strategy for the study. 
                                               
20
  Held with the Coram Community Centre in Mecklenburgh Square, London and Gateway Family Services in 
Birmingham respectively. 
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5.3.4 Stakeholder knowledge-gathering interviews 
In March and April 2013, the Life Study team conducted a number of knowledge-gathering 
interviews with stakeholder representatives. The objectives were two-fold: to understand 
the audience from which the interviewee was drawn (for example, the research community) 
and then to draw on the experience of the individual in engaging and involving participant 
and public audiences in similar studies or related fields of work. 
Twenty interviews were conducted in total and the information gathered was both of 
strategic significance in informing the overarching approaches and principles, as well as 
practical significance in informing specific messages, tools and channels for participant and 
public audiences. 
This evidence was then used to inform the planning of focus groups and in-depth partner 
interviews with participant representatives. This allowed for the concepts, key messages 
and tools that were developed for focus group testing to be based on existing knowledge, 
experience and best practice from other cohorts. 
5.3.5 Focus group and partner in-depth interviews on Life Study concepts and recruitment 
Across May and June 2013, 12 focus groups, of approximately six to eight pregnant 
participants were each conducted over a two hour session. Six of the groups were held with 
the black and minority ethnic (BME) group audiences identified as priority target audiences 
for phase one of the study: Indian, Pakistani and Bangladeshi groups. The other groups were 
held with core or mainstream audiences, which included black African and 
African/Caribbean participants. Women recruited were between 14 and 36 weeks pregnant. 
A spread of participants with differing marital status, working status and maternal age were 
recruited. 
Alongside the group work, 12 couple and family depth interviews were conducted; six of 
these were with BME audiences. The family depths for BME groups included the couple and 
the mother or mother-in-law of the expectant woman. The BME sessions were conducted in 
multiple languages for the mix of language requirements in any one group. For example, 
where a group included both first and second generation Pakistani women, the group was 
conducted in both English and Urdu to cater for all participants’ language needs. 
The sessions investigated participant audience responses to: 
 the ‘idea’ of Life Study 
 the best communications channels to use for reaching participants 
 how to explain the study to participants / language use 
 other key messages and priority information 
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 any alienating concepts that should be considered in the study design (for example, 
biological samples and specific questions) 
 practical considerations of the ‘ask’ of participants (for example, travel requirements and 
childcare arrangements) 
 how to build trust in the study through partnerships and spokespeople. 
The outputs of this research have already been invaluable in assisting the design of study 
materials, reviewing the study protocol (including specific questions and samples) and 
informing the best channels through which to recruit participants to the study pilot which 
ran during November 2013. 
In conjunction with the outputs of subsequent PPI activity used to further refine study 
elements, this focus group research continues to be used into the main phase of the study. 
5.3.6 Existing cohort member discussions 
Members of the Life Study team visited the Born in Bradford (BiB) annual engagement 
event, the Teddy Bears’ Picnic, at the end of May 2013. This provided an opportunity to 
learn directly from existing cohort members about their experiences of being part of the 
cohort, what prompted their initial involvement and what keeps them involved. This is an 
example of the more informal PPI and evidence-gathering that Life Study conducts. 
Team members were able to have one-to-one informal discussions with cohort members 
against the backdrop of the community roadshow-style event and gather firsthand accounts 
of participant experiences. This information has been collated with other audience research 
and is used in all decision-making processes. 
The Life Study team continues to stay in regular contact with the teams from BiB and other 
cohorts, including through the Cohorts and Longitudinal Studies Enhancement Resources 
(CLOSER). 
5.3.7 Cognitive interviews on study protocol questions 
In May and June 2013, the Life Study team undertook a cognitive testing exercise on some 
of the proposed study questions to ensure consistency in participant understanding of 
questions that had not been used elsewhere previously. 
The cognitive testing exercise allowed for participant representatives to feedback on their 
experience of the questions tested and informed any modifications to those elements of the 
questionnaire. This feedback directly influenced the further use of those questions in pilot 
testing. 
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5.3.8 Participant interviews – communications (look, feel and language) 
Alongside the cognitive testing, the Life Study team tested some of the communications 
elements that had already been shaped and focused through previous PPI work. The 
elements tested with 39 individuals - a mix of pregnant women, partners and mothers of 
young babies - were: 
 design palettes 
 imagery 
 communication channels 
 priority information 
 language and accessibility. 
The feedback has been collated with other information gathered through the various PPI 
channels and has been used in development of participant and study materials. 
5.3.9 Testing public engagement methods and activities 
At the end of June 2013, as part of the MRC’s centenary celebration events, UCL hosted a 
science fair and Life Study presented a stall of activities to visitors. 
The event was an opportunity for Life Study to test some of its engagement approaches and 
further the team’s understanding of what interests the public and how to position Life Study 
for maximum impact in the communities it is trying to reach. 
There was an overwhelmingly positive response to Life Study activities from members of the 
public visiting the free event and the activities will be used again at future community 
engagement events locally around Life Study Centres. The activities were specifically 
designed to demonstrate Life Study concepts as follows: 
 Height fortune-teller – using height charts to predict children’s future heights 
 Life Study passport children’s activity book – including genetics and environment questions 
and the child’s Polaroid picture 
 DNA modelling – using sweets to make double-helix models 
 Life Study presentation 
5.3.10 Core pilot processes and materials 
In November 2013, the Life Study team piloted the study with a small number of 
participants. All of the learning from PPI and associated activity up to then was used to 
inform the design of the pilot, the recruitment processes, materials and aspects related to 
participant experience. 
Most elements of the study design, excluding collection of some samples, were tested and 
participants gave feedback on: 
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 Recruitment processes and pathways 
 Recruitment materials 
 The clinic appointment, including 
- Experience, such as waiting times, facilities, length of appt and staff 
- Specific activities, including interviews and questionnaires 
- Travel and travel expenses 
 Post-visit, including 
- Feelings about the whole experience 
- Discussions with others such as GP 
- Any behavioural changes 
This feedback has been used to inform the study design and materials for the main phase. 
Piloting most elements in situ and then collecting comprehensive feedback from 
participants has provided assurance that PPI outputs have been fully embedded in the study 
design as a whole. The previously fragmented feedback on elements of the study that were 
presented out of context has now been validated through this process. 
5.3.11 Enhancement pilot study materials and processes 
In addition to the core study elements, Life Study has received funding for an enhancement 
study specifically focused on the microbiome and infection and immunity. The pilot for the 
infection and immunity enhancement will test with participants the sample collection that 
could not be tested in conjunction with the core pilot. Participant questionnaires have been 
developed and feedback from this pilot is expected to further the team’s understanding of 
the acceptability of requesting specific samples from pregnant women and new mothers, 
barriers to involvement and any refinements or additional communications needed to 
support participation. Maternity staff are also being asked to give their impressions of the 
likely barriers to women’s participation. 
Together with all other PPI activity and outputs, the feedback gained through the infection 
and immunity pilot will provide essential information to prepare Life Study for working with 
participants in the main phase and being responsive to their needs. 
5.4 Development of the main phase materials and audience testing 
It is important to Life Study that all of the information gathered to date from participant 
representatives has been interpreted correctly and that the team is assured that it has acted 
in the best interests of participants in all respects. 
With this in mind, the draft main phase materials that were based on extensive audience 
research and study piloting, were tested with pregnant women and partners on site at one 
of the first NHS antenatal clinics through which main phase participants will be recruited. 
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Pregnant women, and partners if present, were approached in the same way that 
recruitment to Life Study is currently planned. The design of this interaction was considered 
in an attempt to make the feedback authentic and as indicative of future participants’ 
reactions as possible. 
Pregnant women and partners were presented with draft posters, leaflets, postcards and 
participant information sheets and asked by members of the team to comment on: 
 Content – including information provision; Is there anything missing? 
 Design – including imagery, format and paper stock 
 Accessibility – including language, fonts and alternative format requirements 
 Uptake – reactions to the materials and whether from the material presented, they would 
be likely to make a decision to participate in the study. 
The pregnant women and partners involved were also asked to share their demographic 
information so that any trends in responses could be explored. 
All of the feedback from the testing exercise was used to refine the materials, including 
updating the content and design of participant information sheets for the main phase.  
5.5 Other considerations for PPI 
5.5.1 Designing the Life Study Centres 
The Centres will be dedicated Life Study spaces, developed specifically for administering the 
study interviews and questionnaires and taking measurements, observations and some 
biological samples. It is important that the centres are not only physically equipped to allow 
for this, but also designed around the needs of participants. With this in mind, the Life Study 
team undertook a study centre floor mapping exercise involving participant representatives 
in a ‘virtual walk-through’ to collect their feedback on aspects such as ease of access 
between rooms, buggy space, and positioning of facilities and walkways.  As at the time the 
study centres were being specifically designed and refurbished, it was not possible at this 
stage to do a walk-through an existing centre. However, consulting participants at this early 
pre-building stage and then at each decision-making juncture, will be crucial to ensuring 
that the centres meet participant needs. 
5.5.2 Local centre-focused PPI, launch of dedicated PPI groups and community 
engagement 
The Pregnancy Component will be recruited through dedicated Life Study Centres. Whilst 
engagement and PPI to date has been with a range of participant representatives from the 
general population, it is now necessary to focus community engagement and PPI around the 
study centre locations to foster a sense of shared ownership with those specific 
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communities. The Life Study team plans to utilise its relationships with hospital NHS Trusts, 
other local NHS organisations and local authorities, to develop community networks that 
will support recruitment to dedicated Life Study PPI groups, whilst also drawing on existing 
fora. 
Local user groups will have an ongoing involvement in the study, providing a consistent 
resource to be able to draw on for feedback in the initial data collection phases. The benefit 
of establishing dedicated groups is that this allows for knowledge and understanding of the 
study, as well as the working relationship, to build over time. This is especially important for 
Life Study as a complex longitudinal project that will require some level of understanding of 
the study journey. The relationship of the user group members to the study will also mirror 
the ongoing involvement of study participants over an extended time, enabling group 
members to provide informed comment relevant to the stage that participants are at in the 
study. 
It is recognised that each study centre site may require slightly different communication and 
engagement methods and activities to reach the various social and ethnic minority groups 
within these communities. The local user groups will provide insights into the best ways to 
implement this activity. The user groups will also become a central point from which other 
activity (for example focus groups, interviews and online surveys) can be suggested, 
designed and planned with member input.  
Wider local community engagement, including field visits, attendance at community 
meetings and events, and addressing potential participants through local religious 
institutions or community centres, will be built on a solid foundation of local PPI.  
5.5.3 Further focus group research – fathers and partners, hard-to-reach groups 
Through involvement feedback to date, Life Study has already identified some specific 
audiences whose needs require further investigation and understanding.  
The Life Study team is currently planning formal programmes of research with these 
audiences, which include fathers and partners and some hard-to-reach groups, such as 
young parents and vulnerable parents. 
It is likely that these programmes of audience research will take a similar format to previous 
focus group research but will be tailored to these audiences where necessary. For example, 
the style of delivery for the groups and the formats by which feedback is gathered may be 
changed. Some young parents may be more willing to feedback using private fora, one-to-
one, or even via online channels.  
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It is expected that this research will be delivered in the coming months, prior to 
commencement of recruitment, and that the outputs will have influence elements of the 
study design related to participant experience, including recruitment channels, the 
developing design of the study centres, appointment schedules, staff training and 
participant retention.  
5.5.4 Increased use of online and social media for engagement and involvement 
Social media has the potential to positively impact the breadth and depth of Life Study 
engagement and involvement. It provides greater flexibility in the ways that the study is 
able to engage and involve participants and other stakeholder audiences, including via 
discussion fora, online surveys, comments and the like. 
To date Life Study has primarily used online channels as a means of information provision 
and recruitment promotion in relation to the pilot study. However, with the establishment 
of local study centres, locally focused PPI groups and community engagement, social media 
channels will be exploited in a variety of ways to promote engagement and two-way or 
multi-party exchanges. 
Popular pregnancy and young mother websites, such as Netmums and Mumsnet21 will be 
utilised, alongside more local and targeted sites (including fora targeting fathers or ethnic 
minority groups). 
5.6 Future PPI  
Anticipated future public involvement activities might include input into optimal methods 
for promoting and disseminating information about study impacts to participants, for 
example in relation to the use of the data resource and its key findings. Life Study will take 
an active role in publicising key study findings to participants and will draw on the expertise 
of public involvement experts and groups in order to achieve this. Public involvement input 
into ethical study management and data access issues has already been considered within 
the ‘Ethics and Information Governance Framework’ and will evolve as Life Study enters the 
main phase, implements the framework’s principles and develops its resources.  
Members of Life Study will continue to utilise existing links with stakeholders and partners, 
including INVOLVE, a national advisory group that supports greater public involvement in 
NHS, public health and social care research for information on linking with the public and 
the sensitivities surrounding this outreach.  
                                               
21 http://www.netmums.com/ and http://www.mumsnet.com/ (respectively) 
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6 Appendices  
6.1 Appendix 1:  2012 Birth Cohort Study: Call Specification
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A Leadership Team for the 2012 Birth Cohort Study 
CALL SPECIFICATION 
1. Summary 
1.1. The UK has a unique and internationally renowned collection of 
birth cohort studies spanning over 60 years. With funding from 
the Government's Large Facilities Capital Fund we now have an 
exciting opportunity to extend the series with a new study starting 
around 2012, and to maximise the value of the existing studies 
through the development of a new resource to facilitate research 
across the cohorts and with their counterparts in other countries. 
 
1.2. As the first stage in the development of this exciting opportunity, 
the Economic and Social Research Council (ESRC) and the Medical 
Research Council (MRC) are seeking bids to establish the Leadership 
Team for the new UK birth cohort in or around 2012.22 
 
1.3. The new study is intended to support innovative research 
spanning the interface between the biomedical and social 
sciences. To reflect this interdisciplinary approach, proposals to 
provide leadership for the new study must provide combinations 
of skills, knowledge and research experience from across the 
biomedical and social sciences. 
 
1.4. To effect such combinations of expertise, skills and knowledge, 
consortia bids are welcomed. In such cases the lead organisation 
must be clearly identified and plans for the effective and efficient 
management of the consortium must be specified. 
 
1.5. The new birth cohort study will provide a major resource for 
the research community, and also for society generally. To realise 
the full potential of the new UK birth cohort, the data and biological 
samples it generates need to be well managed, accessible to the 
research community, augmented through use and reuse and the 
results of the research to which they contribute widely 
disseminated. 
 
                                               
22 With ESRC providing the lead for the initiative overall. 
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1.6. The successful bidder will provide scientific leadership for the 
study from 1 October 2009 until 31 March 2015. This period will be 
split into two phases. A preparatory phase will be established via 
the award of a contract covering the period 1 October 2009 to 31 
August 2010. This preparatory phase will allow time for the 
detailed elaboration of the study design, work plans and management 
arrangements. Ministerial approval for the release of ‘earmarked’ 
funding will be sought by the Councils in Spring 2010. The 
Leadership Team will assist the Councils with this process. 
Subject to ministerial approval a main contract will then be issued 
to the Leadership Team for the period 1 September 2010 to 31 
March 2015. 
 
1.7. The preparatory phase will not include any piloting of specific data 
collection instruments. It will allow time to establish the feasibility 
of the research design chosen to support the research themes and 
specific hypotheses that the Leadership Team proposes to pursue. 
 
1.8. During the main contract period a minimum of two data 
collections/sweeps across the Cohort will be made. Supplementary 
funding23 may facilitate further observation of study members. 
 
1.9. The closing date for receipt of bids is 4pm, Tuesday 30 June 2009. 
 
1.10. All applicants are expected to submit to ESRC Expressions of 
Interest by Friday 22 May 2009. 
 
 
2. Background 
2.1. Birth and other age or event related cohort studies provide 
important insights into the complex interplay between biological, 
environmental, social, economic and health related experiences and 
conditions. By following individuals over long periods of time and 
with repeated observation, processes of change can be observed. 
By linking change to antecedent experiences and conditions, 
including genetic endowments, researchers have made significant 
progress in identifying causal pathways across the life course. 
These cohorts are significant research resources for biological 
and social sciences especially those that take an 
interdisciplinary perspective. 
 
2.2. While individual birth cohort studies are valuable research 
resources in their own right, if undertaken at regular intervals and 
followed over the life course, they provide a rich basic framework 
                                               
23
 Additional to already being provided by the ESRC and MRC 
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for long term investigations across different generations and time 
periods. The UK has an internationally unique and well established 
series of national birth cohorts, starting with the National Survey of 
Health and Development in 1946,24 the National Child 
Development Study in 1958, the British Cohort Study in 1970 and 
the Millennium Cohort (2000/01)25. Other major birth cohorts 
include the Avon Longitudinal Study of Parents and Children26 – a 
1991 birth cohort of children from in and around the Bristol area. 
 
2.3. In 2007 the ESRC and the MRC made a bid to the Department for 
Innovation and Universities Large Facilities Capital Fund (a major 
source of Government funding for large scale research 
infrastructures) to develop a Birth Cohort Facility. The bid was 
stimulated by the development of the National Data Strategy, 
and in particular the ESRC Strategic Review of Panel and Cohort 
Studies27 which recommended that a new cohort study should be 
established 'in or around 2012' and that cross-cohort collaboration 
should be facilitated. 
 
 
3. The Birth Cohort Facility 
3.1. In July 2008 ESRC and MRC received notification that £28.5 
million had been 'earmarked' from the Large Facilities Capital 
Fund for the Birth Cohort Facility. As noted above, the full release 
of funding is subject to Ministerial approval in spring 2010 once the 
full scientific case (the research rationale) and business case have 
been submitted. The Leadership Team will be expected to work 
closely with the Research Councils in the first six months to 
ensure the strongest possible scientific and business cases are 
developed. 
 
3.2. The proposed Birth Cohort Facility has three main elements. 
These are: 
 a new Birth Cohort Study commencing around 2012; 
 a new Cohort Resources Facility, designed to stimulate research 
across and between existing major cohort studies, providing 
common resources for research purposes and assisting 
with training and development in longitudinal research; 
 a Secure Access Facility, providing research access to sensitive 
                                               
24 See http://www.nshd.mrc.ac.uk/ 
25
 See http://www.cls.ioe.ac.uk/ for details of the 1958, 1970 and Millennium Cohorts. 
26 See http://www.bristol.ac.uk/alspac/  
 
27
 See 
http://www.esrcsocietytoday.ac.uk/ESRCInfoCentre/Images/Strategic%20Review%20of%20Pa
nel%20 and%20Cohort%20Studies tcm6-18161.pdf 
 Page | 62  
 
and/or disclosive data whilst ensuring the safekeeping and 
protection of individual and organisational identities. 
 
3.3. The Wellcome Trust has now joined with the ESRC and the MRC to 
assist with the development of this important new research 
infrastructure. The role and participation of these three funding 
agencies is indicative of the importance that each attaches to the 
need to create new and innovative interdisciplinary research in 
the linked areas of health studies, including cognitive and mental 
development, and social, educational and economic development 
and outcomes. 
 
3.4. This Call Specification for the Scientific Leadership of the Birth 
Cohort Study represents the first stage in the programme of work 
to establish the Birth Cohort Facility. The detailed specification for 
the Cohort Resources Facility and the Secure Access Facility will be 
developed and commissioned at a later date. 
 
4. The Birth Cohorts Facility (BCF) Development Group 
4.1. The specification for the components of the BCF is being undertaken by a multidisciplinary Development Group, consisting of representatives of the medical and social sciences28. The Development Group will be supplemented as required to form a Commissioning Panel to decide the Leadership team for 
the new Birth Cohort Study. 
 
4.2. After careful consideration of a number of study design 
options the BCF Development Group has recommended that the 
design of this cohort should be informed and determined by the 
major social and biomedical/public health research questions and 
hypotheses which the leadership team propose to address. Bidders 
are invited to identify these research themes and hypotheses 
and to present innovative and appropriate research designs to 
address them. 
 
5. The preparatory phase 
5.1. The ESRC and the MRC recognise that bidders cannot elaborate all aspects of the design, development and management of the study in the short time available in which to prepare their bids. What they must demonstrate in their bids is: 
 
 a compelling case for the scientific research themes and 
hypotheses selected within their bid and a justification of the 
over-arching study design they plan to elaborate; 
 the strength and relevance of the interdisciplinary team they 
have assembled to develop these scientific programmes and 
to design, develop, undertake and manage the study and 
subsequent resource, including plans for the management of 
the team; and, 
 an awareness of the complex issues that they will have to 
                                               
28
 Membership of the Development Group and its Terms of Reference are shown at Annex 1 
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address, including ethics and 
governance, data sharing, data linkage, resource management 
and public engagement. 
 
5.2. The successful bid will establish the Leadership Team for the study 
throughout a five and a half year period. An initial contract will 
cover the first eleven months (the preparatory phase) which will 
focus upon the methodology of the study. During this phase the 
Leadership Team will prepare a detailed plan for the design, 
methodology and development of the study during the following 
55 months and will produce the other outputs specified in 
sections 6.11, 6.12, 8.2, 8.3, 8.4 and 10.1. These outputs will be 
used by the Research Councils to assist in obtaining ministerial 
approval for the release of ‘earmarked’ funds. Bidders must 
include details within their bids which indicate how this plan and 
these outputs will be achieved during the preparatory phase. 
 
 
 
6. .Key requirements for leadership of the new Birth Cohort Study 
6.1. This section elaborates further the key requirements, qualities 
and attributes of research leadership that are being sought for the 
development of the design and implementation of the new Birth 
Cohort Study. 
The qualities and attributes of the Leadership Team 
6.2. The new Birth Cohort Study is being developed as a collaborative investment in research infrastructure by the ESRC and the MRC, working closely with the Wellcome Trust. This collaboration reflects the growing need for research which is interdisciplinary, particularly that which brings together biomedical 
and social scientists to research questions which require long term 
and large scale resources. Birth cohort studies provide an 
excellent opportunity to establish close interdisciplinary 
working, following children through vital stages of their early 
physical and mental development, recording and monitoring 
changes in their health, home environment, educational progress 
and other external influences on their development. 
 
6.3. To reflect this aim, the Leadership Team must be structured to 
provide expertise across relevant disciplines. The structure of the 
expertise will relate to two primary and complementary factors: 
the nature of the major research questions that underpin the 
proposed study design and the need to create a high quality 
cohort study as an important future scientific resource. The Team 
Leader is expected to have an outstanding track record in 
innovative interdisciplinary research and demonstrated 
management and leadership skills. The Leadership Team must 
also demonstrate that it has the combination of expertise and 
knowledge to: 
 provide innovative scientific leadership across the range of 
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appropriate key disciplines required to address the high level 
research themes and specific hypotheses to be addressed by 
the study; 
 promote the integration of the range of scientific expertise 
that will be needed throughout the life of the study; and 
 develop a sequenced engagement with stakeholders – these 
will include not only study members and their families and 
potential research users of the information generated by the 
study, but also policy makers and interested members of the 
general public (as the ultimate funders of the study). 
Research issues and the basic design of the study 
6.4. The Leadership Team should identify and justify the scientific 
research themes and hypotheses selected within their bid and 
the over-arching study design they plan to elaborate. Such issues 
will involve close collaboration between social and biomedical 
scientists and will inform both the design of the study and the data 
to be collected from study participants. Examples of such research 
themes include: 
 parenting, child behaviour and risk taking; 
 health, wellbeing, diet and body composition; 
 development, behaviour and childhood education; 
 childhood infections; 
 mental health; 
 biological and environmental influences on health and 
development. 
These are indicative examples only. It is expected that the 
proposal to establish the leadership team will have, at its core, a 
set of themes and related research hypotheses/questions that 
drive the design, the combination of expertise that is brought 
to bear on the research proposed and the nature of the data 
collection29 instruments. These themes need to be as enduring as 
possible throughout the lifespan of the study, thus ensuring that 
a wide range of research areas are addressed. 
 
6.5. The design of the study should reflect both the scientific research themes and hypotheses to be addressed as well as the wider and less specific aim of creating a major national and international resource for future biomedical and social research. Proposers must also bear in mind that the 
Cohort Resources Facility will inter alia, promote comparability 
with earlier birth cohorts. This gives rise to a minimum design 
requirement that the study should contain a national probability 
sample sufficient to allow national estimates to be obtained and, 
where possible, to enable comparability with previous cohorts. 
Those bidding to provide the research leadership must 
demonstrate that they are capable of meeting this. The specification 
                                               
29
 References to ‘data collection’ refer to collection of data of all types. 
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of such a sample (population to be sampled, size of the national 
probability sample and sampling strategy) must be included in bids 
for the leadership of the study. 
 
6.6. Noting that this is a minimum requirement, bidders may wish 
to propose elaborations of the minimal design, for example, 
building upon existing longitudinal resources, area or in-depth 
sub-studies and/or options combined with the above designs. 
These should be related clearly to the research issues to be 
studied and should include an analysis of the advantages and 
disadvantages of the proposed design. 
Other design and methodological considerations 
6.7. Proposers should consider ways through which they would 
incorporate methodological innovation into the design of the 
study, particularly in terms of data collection. Methods of data 
collection could include the use of record linkage, web-based data 
collection methods, or the use of objective measurements of, for 
example, physical activity, geographical location, diet and health 
(both physical and mental). If the collection of blood or the use of 
other invasive techniques in cohort children is proposed, this 
should be justified scientifically and ethically. 
 
6.8. An important element of any long term prospective study is the 
need to retain interest and participation in the study by 
participants. Proposals should include evidence of bidders’ 
awareness of how they might address these issues. 
 
6.9. The BCF Development Group considers that there are strong 
grounds for recruiting the sample (or a large part of it) 
antenatally but post conception. Bidders should give careful 
consideration to this, justifying their chose design scientifically, 
indicating how it might be achieved, and its implications in terms 
of the timetable for the study. 
 
6.10. In the period up to 31 March 2015, a minimum of two data sweeps 
of the Cohort members must be made. These sweeps will provide 
the basic information that the Leadership Team will need to 
undertake research on the proposed theme(s). The observations 
may be supplemented with additional information via record 
linkage. If there are significant scientific reasons for amending the 
contract end date, this will have to be negotiated with the funders 
when the main contact is agreed. 
International linkages 
6.11. There are major benefits to be gained from the analysis of 
birth cohort data in international collaborative research 
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efforts. In order to maximise the potential of the new cohort 
in this respect it is important that the Leadership Team should 
demonstrate awareness of the design of major new birth 
cohorts recently launched or soon to become available in 
other countries. These include the US National Children’s 
Study, the German National Education Panel Study, the 
French Longitudinal Study of Children, ELFE (Growing up in 
France), and other contemporaneous studies. During the 
preparatory phase a plan should be prepared specifying how ties 
might be established with these cohorts with reference to 
potential common design elements. 
Engagement with stakeholders 
6.12. Experience gained from the development of other large 
national cohort studies (e.g. Biobank, Millennium Cohort, 
English Longitudinal Study of Ageing) indicates the 
importance of having an appropriately sequenced 
engagement with the variety of stakeholders. Given the 
needs to retain interest and involvement in the study over the 
participants’ lifetime and to foster public support for its broad 
objectives, considerable efforts must be made to secure 
such engagement at different levels. Proposals should 
contain evidence of bidders’ awareness of these issues. 
During the preparatory phase it is expected that the 
successful bidder will work with the funding agencies to 
prepare a stakeholder engagement strategy. 
 
 
7. Procurement procedures for subcontracted activities 
7.1. The successful bidder will work closely with the ESRC, 
the MRC and the Wellcome Trust to specify and develop the 
infrastructure to collect and link data (administrative records, 
interview data, clinical measurements, etc.) and biological 
specimens of various types (blood, sputum or other 
specimens). Wherever possible, these activities should take 
advantage of existing facilities to achieve the most efficient 
means for the collection, treatment and long-term storage 
of data and biological specimens. If necessary, 
commissioning of sub-contracted activities will have to go 
through OJEU procedures, further information about which is 
available through the OJEU website. 30 
 
7.2. Data collection for the new study will commence in 2012. 
Bidders will be expected to include a broad timetable for 
                                               
30
 http://www.ojec.com 
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activities relating to the collection of data and biological 
specimens. This will need to include consultation on topic 
coverage, preferred OJEU route and piloting. 
 
 
8. Deposition of data and samples 
8.1. The successful bidder will be expected to work closely with 
the funders to agree arrangements to share electronic study 
data and biological specimens, in line with the MRC, ESRC, 
and Wellcome Trust Common Framework for Governance 
Arrangements (Annex 3) at the earliest possible date. This is 
subsequent to any necessary data validation checks, data 
cleaning operations, sample preparation, physical analyses, 
etc. Recognising that the complexity of these arrangements 
will be determined by the nature of the data and specimens 
collected, paragraphs 8.2 to 8.4 below describe the outputs 
in this area which will be required during the preparatory 
phase. Bidders must indicate within their bids their prior 
experience with, and proposals for, the deposition, storage 
and sharing of electronic data and biological specimens. 
 
8.2. A range of options is now available to facilitate the sharing 
of electronic data. These include access via the ESRC/JISC 
Economic and Social Data Service under an end user 
licence, access via Special Licence conditions and access 
through the ESRC Secure Data Service. During the 
preparatory phase the successful bidder will be expected 
to prepare a plan for the deposition of electronic data 
which makes best use of these or similar facilities and is 
consistent with the funders’ policies on data sharing31. 
 
8.3. Dependent upon their nature, biological samples may 
require special transport, treatment, processing and long 
term storage. Arrangements for these aspects must be 
developed and specified in the preparatory phase. 
Bidders should demonstrate relevant expertise and track 
record of specimen archiving in their team. 
 
8.4. During the preparatory phase the successful applicants 
will also be required to develop, implement and maintain 
a Security Plan which will be approved by the Councils, 
                                               
31 See 
http://www.esrcsocietytoday.ac.uk/ESRCInfoCentre/Images/ESRC%20Research%20Funding
%20Guid e tcm6-9734.pdf (ESRC) and 
http://www.mrc.ac.uk/Ourresearch/Ethicsresearchguidance/Datasharinginitiative/Policy/ind
ex.htm (MRC). 
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tested and periodically updated. The Security Plan will cover 
issues relating to Data Protection legislation, disclosure 
control methods and the general management and safe-
keeping of the electronic data, metadata and biological 
specimens collected as part of the study. 
 
 
9. Protection of the identity of study participants 
9.1. The names and contact details of study participants will 
be designated as ‘protected data’ – to be kept separate 
from all other data deriving from the study and to be used 
exclusively for the purpose of maintaining contact with 
study members or for data linkage purposes where these 
have appropriate ethical and/or legal approval. 
 
9.2. The stewardship role32 for protection of this information 
will fall to whichever bodies assume the scientific leadership 
of the study throughout its lifetime. The successful bidder 
will be required to agree to accept this responsibility. 
 
 
10. Governance arrangements 
10.1. The Medical Research Council, the Economic and Social 
Research Council and the Wellcome Trust have 
established a Common Framework for Governance 
Arrangements for Longitudinal Studies (see Appendix 3). 
During the preparatory phase successful bidders will be 
required to work closely with the funders to prepare a plan 
for the governance arrangements for the study in 
accordance with this framework. 
 
11. Timetable, budgetary information and the commissioning process 
11.1. Bids to undertake the scientific leadership of the study 
must be submitted by 4pm on Tuesday 30 June 2009. 
Detailed guidance on the information required as part of 
the application is provided in the 'Notes for Guidance' (see 
para 11.7). 
Timetable 
11.2. A commissioning timetable is attached at Annex 2.  
                                               
32
 See Annex 3 for definition of ‘stewardship’ of electronic data. 
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Budgetary information 
11.3. A total of £28 million (at 100% fEC) is available to set up 
the new Cohort Study.33 This will cover the Leadership Team 
costs and a minimum of two waves of data collection, and 
associated costs. As indicated under paragraph 1.6 at 
present the funds for the BCF are 'earmarked' with full release 
of funds subject to Ministerial approval in Spring 2010. 
Therefore the Leadership Team will initially be appointed via 
the contract for the preparatory phase covering the period 1 
October 2009 to 31 August 2010. Subject to Ministerial 
approval of funds a full contract will then be issued for the 
period 1 September 2010 to 31 March 2015. 
 
11.4. The time provided by the preparatory phase contract will 
ensure that on release of funds the study can remain on 
schedule to commence in 2012 and enable the team to work 
with the ESRC and MRC to develop the strongest possible 
scientific and business case for the study. Bidders should 
note that they will be required to clearly identify the costs 
requested as part of the preparatory phase contract. 
Importance of a Strategic Partnership 
11.5. The ESRC and the MRC will expect the host institution 
to recognise the international importance of the study and 
demonstrate how that articulates with its own broad 
research strategy. The Councils view the development of the 
study as a Strategic Partnership with the host institution(s). 
 
11.6. The ESRC and the MRC will expect the host institution(s) 
to demonstrate a commitment to that partnership. One 
way that this can be achieved is by the host institution(s) 
making an actual contribution to supporting the 
development of the study, as has been the case with other 
major activities recently funded by the Council. This 
contribution could take the form of either Directly Allocated 
or Directly Incurred costs. Bids should thus indicate the 
nature of the proposed host institution(s) support so that 
this can be finalised prior to awarding the contract in 
October 2009. 
                                               
33 This figure of £28 million includes £23 million of funding from the LFCF 'earmarked' 
funds, and additional funding of £3 million and £2 million from ESRC and MRC respectively. 
The remaining £5.5 million of LFCF 'earmarked' funds have been reserved for the Cohorts 
Resources Facility. 
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Application Procedure 
11.7. Full proposals must be submitted to the ESRC by 4pm on 
Tuesday 30 June 2009. Applications should be submitted 
electronically using the UK Research Council’s Joint 
electronic Submission (Je-S)34 form available on the ESRC 
website. Hard-copy, faxed or emailed applications will not be 
accepted. Detailed guidance notes on the procedures for 
completing the form are available at: 
http://www.esrcsocietytoday.ac.uk/ESRCInfoCentre/opportu
nities/current%5Funding%5Fopportunities/. The ESRC 
expects interested parties to submit Expressions of 
Interest by Friday 22 May 2009, although this is not 
mandatory. 
 
11.8. To assist the ESRC in preparing for peer review, and to gauge the 
number of proposals that are likely to be received, applicants are 
required to notify the ESRC of their interest in submitting a proposal 
under this call, advising us of the proposed Research Organisations 
involved in the bid. Applicants should also provide a brief summary 
of their key research themes and hypotheses for the cohort (no 
more than 200 words). The information provided will not be 
published and be used for no other purpose without the 
agreement of the applicant. Expressions of Interest should be 
emailed to birthcohortproject@esrc.ac.uk by Friday 22 May 
2009. Expressions of Interest should not be submitted 
through the Je-S System. 
11.9. Proposals will be assessed in the first instance by external 
referees. These will comprise international leaders within 
relevant scientific disciplines as well as those with expertise 
in the design, conduct or analysis of longitudinal studies. A 
specially convened scientific panel with expertise in large 
scale (social and biomedical) cohorts, will then assess the 
proposals following which shortlisted candidates will be 
invited for interview during September 2009. 
 
11.10. Proposals will be assessed by the Commissioning Panel 
against the following criteria: 
 The originality and importance of the scientific research 
themes and hypotheses proposed. 
 The excellence and innovative features of the proposed 
research and of the study design. 
                                               
34
 See https://je-s.rcuk.ac.uk/  Please note that organisations wishing to register for Je-S should 
contact the helpdesk at JeSHelp@rcuk.ac.uk Tel: 01793 444164 (open 9am to 5pm weekdays, 
except holidays). Users wishing to access the Je-S system for the first time are asked to check 
with their central administration on the status of the organisation's Je-S registration before 
pursuing the option of creating an account through the Je-S system. 
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 The intellectual, leadership and management skills of the 
Team Leader. 
 The capability and experience of the team to carry out the 
work, including scientific and stakeholder engagement skills. 
 Understanding of the requirements (as specified above).  
 The feasibility of the proposed project management plan.  
 Costs and value for money (the ESRC and the MRC are not 
bound to accept the lowest bid). 
11.11. The recommendation of the Commissioning Panel will be 
considered by the ESRC Research Resources Board and the 
MRC Strategy Board in September 2009. 
 
11.12. It is anticipated that the initial contract for the Study will 
be from 1 October 2009 until 31 August 2010. Subject to 
ministerial approval, a full contract will then be issued from 
for the period September 2010 to 31 March 2015. During 
this time a mid-term review will take place where 
consideration will be given to any renewal of the award. It is 
anticipated that the review will take place in order to allow 
sufficient time for the decisions to be made regarding the 
funding of future data collection activities. 
 
11.13. Any enquiries relating to the initiative or to ESRC research 
funding rules should be addressed in the first instance to: 
 
Dr Esther Wilkinson 
Telephone: 01793 413152 
Email: Esther.Wilkinson@esrc.ac.uk 
 
or  Mr Luke Moody 
 Telephone: 01793 444520 Email: Luke.Moody@esrc.ac.uk 
11.14. Any enquiries relating to the Je-S application procedure 
should be addressed to the Je-S helpdesk at:  Tel: 01793 444 
164 
Email: Je-Shelp@rcuk.ac.uk 
 
11.15. Applicants should note that any attempt to lobby ESRC or 
MRC Officers, Peer Reviewers, and members of the 
Development Group, ESRC Research Resources Board or 
Council will result in immediate disqualification of the 
application concerned.  
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Annex 1 
A Leadership Team for the 2012 Birth Cohort 
Study CALL SPECIFICATION 
Annex 1: Birth Cohort Facility Development Group Terms of Reference 
and Membership 
Terms of Reference 
1. The BCF Development Group is appointed by the ESRC Research 
Resources Board to oversee the development of the project to 
implement the new Birth Cohort Facility. 
2. The Terms of Reference for the Group are:  
 to advise on the development of the Strategic Outline Business Case 
and Full Scientific Case; 
 to develop the specification for the scientific teams for both the 
cohort facility and the 2012 cohort study; 
 to advise the Research Resources Board on scientific issues 
regarding the appointment of the cohort facility team, and both 
the 2012 cohort study scientific and data collection teams; 
 to provide guidance to the Research Resources Board on necessary 
stakeholder, user and public consultation and engagement; 
 to consider the impact of the BCF on both existing birth cohort 
studies, and the wider portfolio of current resource investments; 
 to consider lessons learnt from the Understanding Society project. 
Membership 
3. Membership of the BCF Development Group is detailed below. This 
draws its expertise from various academic and 'user' stakeholders. 
Professor Peter Elias (Chair), ESRC Strategic Advisor (Data 
Resources), University of Warwick 
Professor James Nazroo ESRC Research Resources Board, 
University of Manchester 
Professor Maria Evandrou ESRC Research Resources Board, 
University of Southampton 
Professor John Hobcraft University of York 
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Professor Carol Dezateux MRC Centre of Epidemiology for Child 
Health, Institute of Child Health, University College London 
Professor Cyrus Cooper MRC Epidemiology Resource Centre, University of 
Southampton 
Dr Pat Goodwin Wellcome Trust 
Mr Paul Allin Office of National Statistics 
Dr Angela Cooper Medical Research Council 
Mr Matthew Sowemimo, ESRC Director of Communications for Longitudinal 
Studies 
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Annex 2 
A Leadership Team for the 2012 Birth Cohort Study CALL 
SPECIFICATION 
Annex 2: Commissioning Timetable 
Date Activity 
April 2009 Bidders Workshop, Thursday 30 April 2009 (12.30pm to 4.15pm) in 
London. 
June 2009 Closing date for applications for PI team 4.00pm Tuesday 30 
June 2009 
 
July 2009 Peer Review of applications 
September 2009 Commissioning Panel Meeting 
Interviews with shortlisted applicants, week commencing 07 
September 2009 
ESRC Research Resources Board and MRC Strategy Board 
agrees PI team 
October 2009 
Contract(s) finalised for PI team (to start 1 October 2009) 
November 2009 
- December 2011 
Ministerial approval of Full Business Case 
Finalisation of main contract Scientific Leadership Team for cohort 
study. 
Finalise fieldwork 
arrangements. Design and 
pilot study. 
From April 2012 Full Study enters the field. 
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Annex 3 
A Leadership Team for the 2012 Birth Cohort Study CALL 
SPECIFICATION 
Annex 3: Framework for Governance Arrangements for Longitudinal Cohort Studies 
1 Introduction 
Longitudinal cohort studies created through public and charitable funding, and with the 
benefit of public and patient participation, are resources of major importance for 
biomedical, health-related and social scientific research. The funders expect that they 
should be governed, managed and used so as to maximise public benefit. 
To realise the full potential of these studies as research resources, they need to be well 
managed, accessible to the research community, augmented through use and re-use and 
the results of the research to which they contribute widely disseminated. 
Two major considerations have a bearing on the use and accessibility of these resources 
for research - the rights and interests of the research participants (which need to be 
safeguarded, in accordance with legal, regulatory and ethical requirements), and the 
depletability of the biological samples (which necessitate a method for rationing). 
Governance arrangements should be designed to address these considerations. 
Although the detailed governance arrangements will vary, depending on the nature of the 
study, the circumstances of their establishment, their location and the data and samples 
collected, there are many common issues, and certain principles and procedures that 
should be reflected across all studies. This Framework gives guidance on those common 
issues, and on the principles and procedures that should be reflected in the arrangements 
for the management and use of individual studies. 
2 Stewardship 
Good stewardship of each study is critical to the achievement of its full potential as a 
research resource. There are a number of aspects to this, including in particular: 
2.1  Ensuring that use/ access is suitably managed and use maximised. 
Responsibilities include: 
a. devising, articulating and implementing suitable processes for handling use/ 
access; 
b. facilitating and supporting use of the resource; 
c. processing and deciding on requests for access; 
d. ensuring that access/ use is granted in conformity with legal and ethical 
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requirements and the participants’ consent; 
e. policing compliance with terms of access and pursuing infringements. 
2.2 Ensuring the resource is well managed, curated and developed/ enriched. 
This will include: 
a. protecting, preserving, managing, promoting and enriching the resource; 
b. sample and data management and handling/ archiving; 
c. maintaining sample and data security and confidentiality; 
d. seeking and managing core funding and business plans/ charging strategy to 
ensure sustainability; 
e. managing property (in samples) and intellectual property rights in the 
resource; 
f. handling and implementing access requests; 
g. collecting/ handling new data and samples. 
2.3 Managing the relationship with the research participants,  their rights and 
interests and any risk of harm – this includes fulfilling any commitments made to 
them at recruitment (e.g. during the consent process) and at other times, and 
complying with relevant legal, regulatory and ethical requirements. 
Responsibilities in this regard include: 
a. managing contact with participants on enrolment, recruitment, follow up and 
at other stages; 
b. seeking consent from participants (and any further consent as necessary); 
c. ensuring compliance with all legal, regulatory and ethical requirements 
relating to participants (including responsibility to relevant regulators), and 
conformance with participants’ consents; 
d. handling issues relating to feedback of individual or general results to 
participants; 
e. handling issues relating to withdrawal of consent; 
f. handling complaints/ adverse incidents; 
g. addressing new legal or ethical issues arising in the course of the study. 
The institution and staff responsible for stewardship should be clearly identified and 
have the ability to carry out their responsibilities in full. Management and governance 
responsibilities within that should be clearly delineated. Given the importance that 
attaches to these responsibilities, it may be appropriate to establish a Stewardship Board 
with executive powers and Terms of Reference that reflect the duties it must conduct. 
The various responsibilities associated with stewardship may be shared between several 
institutions, or delegated or assigned to a separate body, provided this is consistent with 
legal and regulatory requirements and that participants remain clear about the 
arrangements, and how and by whom their interests are being safeguarded. The carrying 
out of these responsibilities may be subject to independent oversight, either through 
existing regulatory mechanisms (e.g. the NHS Research Ethics Committee) or a special 
mechanism created for the study (e.g. the UK Biobank Ethics and Governance Council). 
3 Access management 
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Arrangements for access should be designed to ensure that research use is permitted as 
rapidly and widely as possible so as to maximise public benefit from the resource, with 
due regard to the legal and moral responsibilities of the study to the research participants. 
3.1 Mechanisms for access/ data sharing 
Depending on the range and sensitivity of the data and samples collected, a suite of 
mechanisms to share data and provide access may be appropriate to ensure that access is 
maximised. Any controls applied should be proportionate to potential risks, should not 
create unnecessary barriers to research and the various routes for access clearly explained. 
Access to samples or to participant-related data that carry a risk of direct or indirect 
disclosure of personal information will require the highest degree of management and 
control, with the samples and data only being accessible by application. The materials 
may then be provided directly to the researchers, possibly in limited amounts (to reduce 
the disclosure risk), under the control of an access agreement, or via a safe setting. Less 
sensitive data, particularly non-disclosive datasets, may be suitable for sharing more 
openly, for example, through limited access websites with secondary controls, or on 
openly accessible websites. 
3.2 Procedures for managing access 
General requirements 
Procedures for access to and use of the resource should be clearly articulated to 
participants and potential users. All access to and use of the resource for research, 
including by the investigators involved in creating the resource, should be governed by 
those procedures. 
Access to the resource should be open to all researchers on a non-exclusive basis, for the 
research purposes for which the study was established, within the terms of the 
participants’ consents. Access procedures should be fair, open and transparent and not 
unnecessarily obstruct or delay research use of the resource. 
Procedures may differ for access to different parts of the resource (e.g. access to data 
repositories versus access to samples), to different types of data (e.g. data that is highly 
disclosive versus fully anonymised data; raw versus augmented data), or to link data (e.g. 
phenotype to genotype). In particular, the level of scrutiny and independent review may 
vary according to the level of risk/ sensitivity. In each case, procedures should be 
proportionate to the risks and sensitivities associated with the materials concerned. Co-
ordination across mechanisms to ensure consistency between parts of the resource will 
be essential. 
Application process for managed access 
The development of access applications should be facilitated and encouraged through the 
provision of information promoting the resource and highlighting the data and samples 
available, either openly, by application, or otherwise. 
Any application for access to data or samples should be accompanied by a clear 
statement of the proposed research use and should include sufficient information to 
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enable the steward of the resource to establish that the material requested is relevant to 
and appropriate for that purpose. 
Where not separately undertaken (e.g. as part of the funding process), independent 
scientific review and ethical approval of applications to use samples or data may be 
required and consideration should be given to the needs for this as part of the access 
application process. 
Decision-making 
Responsibility and authority for decision-making ultimately rests with the steward of the 
resource. This may be delegated or assigned to a particular group or body, or in some 
cases, an individual, provided it is clear where the responsibility and authority in any 
particular case lies and the decision-makers are accountable for their decisions. Care 
should be taken to avoid separating responsibility and authority. 
Decision-making processes should be clear, transparent and timely. They should involve 
the provision of expert advice where necessary. They should also include mechanisms 
for managing conflicts of interest. 
 
Independent involvement in decision-making 
In many cases, and particularly for large national resources, independent involvement in 
decision-making may be necessary: 
a. To manage conflicts of interest, or  
b. To represent or speak from the perspective of the participants. 
This could involve the inclusion of independent voice(s) in a Stewardship Board, or 
some form of independent review mechanism. This should be clearly articulated in the 
decision-making structure and in the terms of reference of any bodies including such 
independent input. 
Criteria 
Criteria for access, including eligibility criteria and criteria for prioritisation of access to 
depletable samples, should be transparent and objective, and designed to maximise the 
research value of the resource for public good. 
Referral 
Instances may arise where, for various reasons, an application to access data or samples is 
rejected. In the vast majority of cases, the grounds for refusal will be clear, justifiable and 
acceptable to the applicant. To address the unlikely situation where this is not the case, 
the steward should consider implementing mechanisms to resolve disputes to the 
satisfaction of all parties. This may involve utilising internal escalation procedures in the 
first instance. This should be explicitly defined. Rarely, situations may arise where there 
is an unresolved tension, for example, between the scientific value of the proposed 
research use and the participants’ interests. Such cases may be referred to the funders 
who may seek expert advice or review in determining a potential solution. 
Implementation 
Once an access application has been granted, the request should be processed promptly. 
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Requests may need to be prioritised if they are numerous and resources are constrained. 
3.3 Terms of access 
De-identification prior to release 
Data and samples will only be available for use within the participants’ consents. The 
consents may limit use of the data and samples to use in anonymised form. Even where 
this is not the case, the risk of disclosure of participants’ identities to researchers should 
be avoided, except where this is necessary and justified in the access application, to 
minimise the risk of harm. This will generally mean that data and samples should be de-
identified as far as possible prior to release. Researchers who gain access to resources 
also have a responsibility to ensure they do not attempt to identify individuals (outside 
the agreed purposes of their research) or claim to have done so. 
Access agreements 
The user and, in some circumstances his/ her institution, should be asked to sign a 
licence agreement and/ or a material transfer agreement with the steward of the resource. 
These agreements should set out the terms of access. The steward of the resource may 
need to police compliance with these agreements and consider applying sanctions in the 
event of breach, or misuse of data and samples. Issues of non-compliance that cannot 
be resolved between the parties may be referred to the funders for consideration. 
Specification of access agreements 
Access agreements are likely to specify some or all of the following terms and conditions: 
- the researcher(s) and their institution(s) authorised to use the materials; 
 
- details (and a delimitation of) the purpose for which the data and samples may 
be used; 
- details of the ownership of research results; 
- obligations concerning the dissemination and publication of research results and 
return of data/ samples to the resource; 
- licence fees, if applicable; 
- duties of confidentiality including undertakings to ensure that participant  
anonymity is maintained; 
- limits or prohibitions on onward transfer of data or samples; 
- limits or prohibitions on the linking of data with other data or samples; 
- prohibition on recontacting research participants; 
- (for transnational access) additional protections concerning foreign legal 
jurisdictions; 
- details of any requirement concerning the acknowledgement of the use of the 
resource; 
- details of any conditions for data/sample transfer, management, storage or 
security 
- other requirements necessary to ensure compliance with the responsibilities of 
the resource to the participants (which, depending on the arrangements with 
participants, could include obligations in relation to individual health deriving 
from data or samples, obligations in the event of withdrawal of consent and 
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compliance with any other terms of the consents); 
- details of any ethical requirements; 
- standard legal disclaimers regarding quality/ errors and 
- provision for the consequences of any breach. 
Exclusivity 
Access to data and samples should not be granted exclusively, though the sharing of 
research results may be delayed in certain circumstances for short periods to allow 
researchers to publish their findings or seek patent protection. 
Generally, no preferential access should be given to those involved in the creation of the 
study, on the basis that the purpose of creating the study is to develop a resource for the 
whole research community, to which access will be granted openly, or controlled and 
prioritised on the basis of scientific merit. Those involved in the creation will of course be 
particularly well placed to gain access on the basis of scientific merit alone. 
However, there may be situations where a study is created, or a new sweep conducted, 
for the primary purpose of testing specific hypotheses. In these situations, the funders 
may consider allowing the investigators concerned a reasonable delay before sharing the 
data and materials more widely in order to fulfil the study’s (or the sweep’s) primary 
purpose. This will need to have been considered as part of the original funding proposal.
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6.2 Appendix 2: Flow Diagram of Life Study 
Life Study Flow Diagram
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6.3 Appendix 3: Sample Size and Sampling Methodology 
6.3.1 Summary of conclusions on sample size and statistical power presented in original 
scientific case 
A full technical report of the Life Study power calculations was presented for the 2009 bid. 
This was reviewed in 2013 when further information on sample size was discussed by the 
SSC and ISAC and then presented to the Life Study Corporate Board in June 2013 (LSCB 13/1 
Annex 3). This informed the funders’ approval to release funds for the Innovation Phase 
(Phase 1) and were part of the Life Study Business Case version 12.3. 
Scientific progress on the five research Life Study themes demands that there is sufficient 
power to enable reliable detection of moderately strong causal effects of risk factors 
(environmental, psychosocial, genetic) that are moderately common (e.g. prevalence ≥ 10%) 
on outcomes that are other than rare (e.g. prevalence ≥0.5%).  
Such outcomes include: asthma (>5%); ADHD [DSM IV] (4%); strabismus (2%); and idiopathic 
epilepsy (0.5%). The calculations demonstrate these criteria to be satisfied by 100,000 
recruits but not 50,000. 
A sample size of 100,000 subjects provides adequate power to detect associations between 
determinants of modest or large effect and binary traits that are present in the cohort with 
a prevalence of at least 1%. 
A sample size of 100,000 recruits provides excellent power for quantitative traits. The power 
of such traits will also be of central importance to the analysis of key traits within and 
between ethnic groups which is fundamental to our overall research program. Our sampling 
model will ensure sufficient participants in 3 ethnic groups (White European, South Asian 
and Black) for analysing quantitative traits, but there will also be sufficient power for some 
binary traits 
The Life Study is an effective platform for genome wide association or sequencing studies 
particularly when they are based on quantitative traits. 
A sample size of 100,000 is appropriate for the full cohort. In coming to this conclusion, it is 
noted that the apparent requirement could be reduced by ignoring the relevant bio-analytic 
complexity that is taken into appropriate account in our calculations. Ignoring realistic levels 
of such complexity can easily halve the apparent sample size requirement.  But evidence 
from the genomics world suggests that if studies are designed with unrealistically small 
sample sizes, real effects are hard to detect and most reported effects are false positives.  
This is seriously detrimental to the advancement of biomedical science. 
The US National Children’s Study (NCS) also viewed case-control analyses based as being a 
key determinant of statistical power and also selected a sample size of 100,000. Taking full 
account of differences in the two sets of assumptions, our estimates of statistical power are 
more conservative than theirs but the difference is relatively small. The sample size 
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calculations from the December 2012 US NCS ‘White Paper’ have been reviewed and in brief 
demonstrate, albeit more conservatively than the Life Study calculations, the statistical 
power expressed for different disease outcomes.  The frequency of these outcomes is 
mostly comparable with those estimated for the UK.   
Key results of Life Study power calculations from 2009: 
Table S1: Environmental Main Effects 
Statistical power (at p<0.01) to detect a relative risk of the size stated with 100,000 subjects 
Prevalence of 
disease 
5% 2% 1% 0.5% 
Relative risk*     
1.5 0.5** =>99% 
0.2** =>99% 
0.1** =  88% 
0.5** = 96% 
0.2** = 74% 
0.1** = 42% 
0.5** = 68% 
0.2** = 38% 
0.1** = 19% 
0.5** = 34% 
0.2** = 17% 
0.1** =   8% 
1.67 0.5** =>99% 
0.2** =>99% 
0.1** =  98% 
0.5** =>99% 
0.2** =  97% 
0.1** =  63% 
0.5** = 88%        
0.2** = 71% 
0.1** = 30% 
0.5** = 53% 
0.2** = 36% 
0.1** = 13% 
2.00 0.5** =>99% 
0.2** =>99% 
0.1** =>99% 
0.5** =>99% 
0.2** =>99% 
0.1** =  93% 
0.5** =>99% 
0.2** = 95% 
0.1** = 62% 
0.5** = 82% 
0.2** = 67% 
0.1** = 30% 
*Relative risk associated with “at risk” environmental exposure v “not at risk” 
**Prevalence of “at risk” environmental exposure 
 
Table S2: Genetic Main Effects 
Statistical power (at p<10-4) to detect a relative risk of the size stated with 100,000 subjects 
Prevalence of 
disease 
5% 2% 1% 0.5% 
Relative risk*     
1.5 0.3** =>99% 
0.1** =>99% 
0.05** = 98% 
0.3** =>99% 
0.1**   = 87% 
0.05** = 46% 
0.3** =  94% 
0.1** =  37% 
0.05** = 11% 
0.3**  = 49% 
0.1**   = 8% 
0.05** = 2% 
1.67 0.3** =>99% 
0.1** =>99% 
0.05**=>99% 
0.3** =>99% 
0.1** =>99% 
0.05** =89% 
0.3** =>99%        
0.1**  =  77% 
0.05** = 39% 
0.3**  =  84% 
0.1**  =  27% 
0.05**=  9% 
2.00 0.3** =>99% 
0.1** =>99% 
0.05**=>99% 
0.3** =>99% 
0.1** =>99% 
0.05**=>99% 
0.3** =>99% 
0.1** =>99% 
0.05**=>85% 
0.3** =>99% 
0.1** = 77% 
0.05**= 34% 
*Allelic relative risk under additive genetic model 
**Minor allele frequency (MAF) 
Tables S1 and S2 indicate that a sample size of 100,000 subjects provides adequate power to 
detect associations between determinants of modest or large effect and binary traits that 
are present in the cohort with a prevalence of at least 1%. Furthermore, if the trait 
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prevalence is as low as 0.5% there is still acceptable power for meaningful analysis if the 
exposure prevalence is high or the relative risk is large. Rarer determinants of small 
magnitude affecting rarer traits (≤0.5%) demand pooled collaborative analysis with 
harmonized cohorts to achieve adequate statistical power. 
Figure S1 
 5% 2% 1% .5%     5% 2% 1% .5% 
1.5        1.5     
1.67        1.67     
2.0        2.0     
 
 
Using the same shading as tables S1 and S2, figure S1 provides a schematic representation 
of the fall in statistical power obtained (for both the environmental and the genetic effect if 
the overall sample size is reduced to 50,000 recruits. 
6.3.2 Summary of conclusions on sample size and statistical power prepared in June 2013 
In mid-2013 Professor Burton replicated the sample size calculations carried out in mid-2009 
using the same methodology and a wider range of sample sizes from which Francesco Sera 
the Life Study survey statistician compiled the following power curves.   
Professor Carol Dezateux compiled the outcome and exposure data using UK estimates.  The 
following tables and graphs summarise the findings.  
The power curves presented  give – firstly, curves for environmental main effects for a range 
of outcome prevalences (10%, 5%, 2%) and two exposure prevalences (10% and 20%); and 
secondly, for the genetic main effects using two allele frequencies (5% and 30%) for the 
same outcome prevalences. 
In summary under the extreme considerations represented in these analyses (binary 
outcomes and binary exposures) power is preserved for all but environmental main effects 
at 2% outcome prevalence for a sample size of 50-60,000 in the Pregnancy Component.   
A further written commentary by Professor Burton was considered: 
“Looking over the revised power profile, the results demonstrate that data on 50,000 
participants will provide acceptable power to study the key classes of question that you 
100,000 recruits 50,000 recruits 
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wish to study. In saying this, however, it is important to recognise that 50,000 original 
recruits never translate into 50,000 usable participants for any particular analysis. In 
consequence I’d tentatively suggest that you probably ought to aim for 60,000 initial 
recruits on the basis that this will provide you with at least 50,000 subjects with complete 
data for many things you’ll then study. 
Although the power for environmental determinants on rare (<2% prevalence) phenotypes 
(e.g. neurological conditions) may appear to be limited (odds ratios need to be close to 2.0 
to get power up near 80%), many non-genetic factors considered to be of epidemiological 
interest are associated with large odds ratios. This is not least because, unlike genetic 
variants, they are not protected by Mendelian Randomisation and so small odds ratios are 
rather difficult to interpret anyway.  
For the purposes of the power calculations, non-genetic determinants have been modelled 
as binary whereas in reality more and more non-genetic factors are being measured as 
continuous variables. This includes, for example, quantitative measurements of biomarkers 
and these are in general considerably more powerful than binary measures. The increasing 
use of high throughput multi-endpoint biomarkers is one of the most important reflections 
of our enhanced capacity to measure not only the state of health of individual participants 
but also their environmental exposures. In the same way many measures of the wider 
environment (e.g. pollution) are naturally quantitative in nature, as too are many of the key 
scales and measures in psycho-social science.  
Consequently, I am confident that the power profiles for binary non-genetic determinants 
underpin what will actually be a very healthy capacity to study quantitative environmental 
determinants as they become increasingly available, and also gene-environment 
interactions.”  
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Table S3: Outcome and exposure prevalences expected in UK children in early childhood 
Outcome 
 
Definition 
 
Age 
(years) 
Prevalence of 
outcome (%) 
Expected n 
per 50,000 
Source 
 
Preterm birth1 < 37 weeks 
gestation 
0 6% 3000 Moser et al 
2005 
Asthma 
phenotypes2 
Parental 
report/doctor 
diagnosed 
asthma 
3 years 11.7% 5850 MCS 
Obesity4 BMI obese 3 years 5% 2500 MCS 
  5 years 5% 2500 MCS 
Overweight3 BMI 
overweight 
3 years 18% 9000 MCS 
Longstanding 
illness4 
Parental report 3 years 15.8% 7900 MCS 
Recurrent ear 
infections5 
Parental report 3 years 6.5% 3250 MCS 
Autism 
spectrum 
disorders5 
Parental report 
of doctor 
diagnosed 
7 years 1.7% 850 MCS 
Learning 
disabilities6 
Special 
educational 
needs with 
statement 
7 years 2% 1000 English school 
administrative 
data6 
Exposure Definition Timing Prevalence of 
exposure 
Expected n 
per 50,000 
Source 
Tobacco use 
in pregnancy 
Smoked before 
or during 
pregnancy 
Pregnancy 26% 13000 Infant 
Feeding7 
Survey 2010 
 Smoked 
throughout 
pregnancy 
Pregnancy  12% 6000 Infant 
Feeding7 
Survey 2010 
Maternal 
alcohol 
consumption 
>3 times a 
week  
child age 9 
months 
15.7% 7850 MCS8 
 
                                               
1
 Moser et al Health Stat Q. 2008 Autumn; (39):22-31, 34-55. 
2
 Henderson et al Thorax 2008; 63: 974–980. doi:10.1136/thx.2007.093187 
3
 Griffiths LJ et al Int J Pediatr Obes. 2011 Jun;6(2-2):e423-3 
4
 Millennium Cohort Study 2
nd
 Survey: A User's Guide to Initial Findings; Hansen, Joshi 2007 
5
 Russell J Autism Dev Disord. 2013 May 30. [Epub ahead of print] 
6
 Meschi, Micklewright, Vignoles & Lindsay DfE research report DFE-RR247-BCRP11 published December 2012 
7
 Infant Feeding Survey 2010: Early Results NHS Information Centre 2011 
8
   Millennium Cohort Study 1
st
 Survey: A User's Guide to Initial Findings; Dex, Joshi 2004 
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Figure S2: Power curve environmental main effects: outcome 10% exposure 10% 
 
Figure S3: Power curve environmental main effects: outcome 5% exposure 10% 
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Figure S4: Power curve environmental main effects: outcome 2% exposure 10% 
 
Figure S5: Power curve environmental main effects: outcome 10% exposure 20% 
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Figure S6: Power curve environmental main effects: outcome 5% exposure 20% 
 
Figure S7: Power curve environmental main effects: outcome 2% exposure 20% 
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Figure S8: Power curve genetic main effects:  outcome 5% MAF 30% 
 
Figure S9: Power curve genetic main effects:  outcome 2% MAF 30% 
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Figure S10: Power curve genetic main effects:  outcome 10% MAF 5% 
 
Figure S11: Power curve genetic main effects:  outcome 5% MAF 5% 
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Figure S12: Power curve genetic main effects:  outcome 2% MAF 5% 
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for example) and by relating this to the Pregnancy Component to understand any selection 
biases or confounding structures within and across each sample. 
6.3.3.2 Sample design for the Birth Component 
Sampling for the Birth Component has two stages.  The first stage consists of the selecting a 
random sample of Primary Sampling Units (PSUs).  The second stage is the selection of a 
sample of births from within each PSU. Middle Super Output Areas (MSOAs) are likely to be 
appropriate as PSUs as 2011 Census of Population data is available at this level of 
geographical detail, providing indicators of ethnicity and social background, and there is a 
reasonably balanced population distribution across MSOAs.  
The Birth Component sample will be based on birth registration records as these include 
information on the age, address, name and occupation and country of birth of the mother 
(and the father for married couples and those who are not married but co-register the 
birth). In England and Wales, birth records include linked information provided by the 
midwife when registering the baby to obtain the NHS number (including birth weight, 
gestation and ethnicity of the mother). The allocation of birth records to PSUs will involve 
the statistical authorities for England and Wales, Scotland and Northern Ireland.  
After sampling procedures have been agreed with the national statistical agencies (or the 
Data Linkage Service) they will be tested in a ‘dry run’ before the sampling procedure goes 
live to ensure that the processes are understood and work as intended within the desired 
timeframe. 
6.3.4 Harmonisation of the Pregnancy and Birth Components 
6.3.4.1 Data analysis: the user 
A set of statistical weights are required to allow the research user to analyse the Life Study 
data as a single integrated dataset, rather than as separate Pregnancy Component and Birth 
Component samples. This facilitates inferences to the whole population of UK births.  
The weights that are produced should be straightforward to apply in analyses with 
appropriate guidance to users. Most software packages will provide a facility for weighted 
models and associated robust standard errors. For the clustering aspect of the sample (over 
both components) it is suggested that multilevel models are used to take account of cluster 
variation. Pilot analyses will be carried out before data are released to study any issues that 
may arise and provide guidance for users. Information about the computation of weights 
will also be available to all users. The use of multiple imputation will be studied.  
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6.3.4.2 Temporal alignment of sampling 
Reliably generalising from the Pregnancy Component to the national population using 
information from the Birth Component requires that the two samples are recruited in 
concert. The potential for evaluating secular trends makes it essential that information from 
the Pregnancy Component can be anchored in information derived from a Birth Component 
that is contemporaneous.   
Birth Component interviews will be timed therefore to correspond with the 6 month 
interviews in the Pregnancy Component. Over the four years of the study, this implies that 
the Birth Component 6 month interviews should be completed at the rate of approximately 
420 per month. To gain temporal alignment with the first 6 month interviews conducted at 
Life Study Centres, home visits with the mother and fathers/partners within the Birth 
Component will commence in March 2015. 
6.3.4.3 Weighting and overlap between the two samples 
The methods to be used for the calculation of sample weights for the Birth Group depend 
on the extent to which access can be given to the personal information contained within 
birth records (including the linked maternity records) for all live births in each sample 
period.  Access to national birth registrations is being sought from ONS under Approved 
Researcher Status as set out in the Statistics and Registration Act 2007 and would permit Life 
Study statisticians to access data through the ONS virtual micro-laboratory and to analyse 
these records having added a response marker to the national data files.  This procedure 
would be performed for both Birth Component and Pregnancy Component samples to 
provide users with the means to integrate the two samples for analytical purposes, thereby 
achieving an increase in the power of statistical estimates derived for the Life Study. 
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6.4 Appendix 4: Pregnancy Component – selecting maternity units  
6.4.1 Background 
In the original submission (mid 2009) data for the year 2007 were extracted from the 
national births register for England and Wales and from the Health Care Commission Survey 
and used for the sampling frame to categorise births by residence and by maternal ethnicity. 
This information was then used to review and identify potential geographic locations for Life 
Study Centres, taking account of the co‐located maternity units and their birth rates and the 
ethnicity of the births delivering in those units. 
6.4.2 Principles for maternity unit selection 
An important scientific objective was to over‐represent the main black and minority ethnic 
[BME] groups. BME births are clustered in the UK, as most BME groups reside in England; 
98% of the Asian and 98% of the Black population live in urban areas. As a consequence of 
this, there will be some under‐representation of those living in rural areas and the most 
socially deprived quintiles may be overrepresented. These implications were discussed at 
peer review and subsequently, and these trade‐offs were agreed to be acceptable. 
Each Life Study Centre should be located in proximity to the maternity units ‘feeding’ into it, 
to support good recruitment rates over the time period. In the original application it was 
assumed that women would not travel more than 30 km to attend a Life Study Centre. 
6.4.3 Original modeling (2009) 
Modelling of births to identify choice of maternity units for the original application was 
carried out at the Small Area Health Statistics Unit (SAHSU), Imperial College, using 
confidential datasets including full postcode of residence registered at birth, under special 
licence. Additional information was provided by the National Perinatal Epidemiology Unit 
(NPEU). Preliminary modelling assumed a 35% recruitment rate, selected as an extremely 
conservative and achievable figure, although the recruitment rate is likely to be 
considerably higher based on experience from ALSPAC and the Millennium Cohort Study 
(around 70%) and the Born in Bradford cohort study (80%). 
In the original application ten Life Study Centres were proposed but this was reduced to 
eight Life Study Centres (in England, Wales and Scotland) in order to create the resources 
needed to meet the requirement to include a national probability sample (to receive home 
visits as in the Millennium Cohort Study). A Life Study Centre in Northern Ireland was not 
considered cost effective given the population density. It was estimated that these eight 
centres would result in a recruited sample of 93,000 women and babies. 
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6.4.4 Updating the maternity unit model in the preparatory phase (2012) 
Work to update the maternity unit figures and create a revised list of eligible maternity units 
for the study was undertaken at the SAHSU, with additional advice from the NPEU and 
working closely with the Life Study team. All births in 2010 recorded in the national births 
register, maintained by the Office for National Statistics (ONS) and held at the SAHSU, were 
mapped by postcode of residence at the time of birth and by maternity unit at delivery in 
order to map the catchment areas of the various maternity units. Based on these data, the 
number of maternity units and the numbers of births in each maternity unit that would fall 
into different distance bands from the proposed Life Study Centres (5 and 10km) were 
calculated.  
The choice of maternity units was driven by a rich mix of maternal ethnicity (based on the 
Care Quality Commission’s Maternity services survey 2010), the unit’s clinical network and 
the compactness of the catchment area. The location of Life Study Centres were selected 
based on the proximity to the maternity units, public transport hubs and shopping areas.  
Estimates were made for different recruitment response rates, namely 50%, 60% and 70% 
response rates respectively and for 12, 18 and 24 month durations of recruitment. The 
modelling assumed that response rates are similar across the different ethnic groups. The 
ONS prediction for a 5% increase in births from 2010 to 2014/2015 when recruitment to the 
main study will start was also taken into account (% increase 2010 to 2014: 4.9%; % increase 
2010 to 2015: 4.8%). 
These data suggested that a target sample of over 93,000 births might be achieved with an 
18 months recruitment period depending on response rates.  
6.4.5 Revisions to the maternity unit model in the pilot phase (2013)  
The original Life Study design was based on an 8 centre model. During the pilot phase, it 
became clear that maintaining 8 centres would not be feasible within the original budget. In 
order to maintain the scientific value of the original proposal, a revised design required: 
 a sufficiently large sample size to address the original scientific objectives, 
 a good ethnic, socioeconomic and geographical diversity among participants recruited,  
 at least one prenatal visit to ensure a rich resource of pregnancy data, and 
 two postnatal visits to maintain the richness of phenotypic data. 
During 2013, business-processing and cost models were scrutinised by the Life Study SSC 
and LSSAC, as well as representatives of the funding bodies. The preferred revised option for 
Life Study was to recruit from four Centres for 30 months with two postnatal visits. This 
maintained a large sample size of over 60,000 babies with a 50% recruitment rate, and 
ensured good ethnic, socioeconomic and geographical mix and maintained two visits.  
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6.4.6 Implications of evaluation at end of Phase 1 
As significant uncertainties persist in relation to recruitment rate and operational 
complexity, it was agreed that the first two centres would open and be evaluated in Phase 
1. The opening of further centres in Phase 2 (mid-2016) will depend upon successful 
recruitment and operations in Phase 1. This evaluation will take place around the time of 
Government Gateway Review 4b.  
If the study is unable to progress to Phase 2, Life Study Centres 1 and 2 will complete data 
collection and postnatal visits on all participants recruited and maintain longitudinal follow-
up until October 2017. To ensure that data from the UK-wide representative Birth 
Component sample can be integrated with the Phase 1 Pregnancy Component sample, the 
Birth Component will commence recruiting in Phase 1 and will continue to recruit alongside 
the Pregnancy Component until it reaches the target sample size of 20,000 participants. 
The number of recruited participants in Phase 1 is still likely to be greater than total sample 
sizes in previous cohorts. Phase 1 alone would provide a valuable nationally representative 
resource with greater pregnancy coverage and richness of biomedical data than previously 
achieved in a national longitudinal cohort study, despite potential limitations in addressing 
some of the original research objectives. The full potential of Life Study to address the 
original study aims will be achieved by Phases 1 and 2 combined. 
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6.5 Appendix 5: Recruitment Pathways 
 
Note: Pregnancy Component referred to as Pregnancy Group in this diagram
Life Study Pregnancy Group recruitment pathway – integrated NHS model
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6.6 Appendix 6: Protocols for the physical measurements 
 
The Standard Operating Procedures for anthropometry, vision and child development 
assessments are available as separate reports for download on the ‘Resources’ page of the 
Life Study website www.lifestudy.ac.uk. 
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6.7 Appendix 7: Survey and Interview Schedules 
Appendix 7 provides an overview of the survey and interview questions included in the final 
scientific protocol. All questionnaires which were designed, scripted and, where relevant, 
were in use at the time Life Study closed, are available as separate reports for download on 
the ‘Resources’ page of the Life Study website www.lifestudy.ac.uk. 
6.7.1 Background to survey and interview topics  
6.7.1.1 Parents and families 
The topics and question areas included within the ‘Parents and Families’ module are shown 
in Figure 1. 
Figure 1: Parents and families module 
 
6.7.1.1.1 Identity: ethnic, national and other identities 
The large study sample will allow analyses within and between different cultural and ethnic 
groups, including the relationship between identity and child outcomes, and 
intergenerational social mobility among families from different cultural backgrounds.  
Life Study will collect information on the: 
 cultural, ethnic and religious identities of the child’s mother and partner;  
 migration status of parents and grandparents 
 languages used in the home and with the baby.  
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6.7.1.1.2 Parents’ health and lifestyle 
A significant focus will be on parents’ health lifestyle during and after pregnancy, including 
physical activity, alcohol, smoking, diet and nutrition, and their influence on child outcomes. 
Pregnancy and the early postnatal period are also times when women and their partners 
make behavioural changes, including quitting or reducing smoking and alcohol intake, 
changing their diet and often reducing or changing the type of physical activity they 
commonly undertake. Obesity or greater weight gain in pregnancy are associated with more 
extreme vascular and metabolic changes and increased risk of later adverse outcomes in 
women. Little is known about the levels and impact of maternal physical activity in 
pregnancy on infant and longer-term child outcomes.  
Life Study will collect information about: 
 parents' views of their own health, including longstanding limiting illness 
 hospital admissions 
 regular medications.  
6.7.1.1.3 Mental health, well-being and cognitive and non-cognitive traits  
Life Study will enquire about parental mental health, parental well-being, parents’ cognition 
(IQ), and non-cognitive constructs, such as parental self-efficacy and personality traits. A 
wider range of mental health disorders will be explored in both mothers and partners than 
have typically been covered in national birth cohort studies, including anxiety and 
depression, past mental health problems, ADHD and autism traits. This will allow an 
understanding of how both mothers’ and fathers’ mental health contributes to a range of 
emotional and behavioural disorders that present in young children, many of which have 
been increasing in prevalence in recent years. Repeated observations will help clarify the 
effects on children of enduring compared to episodic problems.  
Measures of IQ and personality traits will be collected from both mothers and partners. 
These will be key for understanding the strong intergenerational links in cognitive ability and 
in non-cognitive traits between parents and their children, and help map the complex 
interplay between parenting behaviours, environmental and genetic factors. 
6.7.1.1.4 Education and employment, and financial situation 
Birth outcomes and early infant development are strongly patterned by parental 
occupation, education, and measures of family economic status such as income and wealth. 
Life Study will provide important new insights into the early causes and mechanisms for the 
transmission of disadvantage across generations. It will allow researchers to understand the 
impact on developmental outcomes of the interactions between social and socio-economic 
inequalities, biological and environmental factors, and parental behaviours before birth and 
in the first year after birth.  
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Questions on education, employment and occupation have been designed to ensure 
continuity and comparability with the key socio-economic indicators of previous birth 
cohort studies. This will enable cross-cohort comparisons on important policy issues such as 
social mobility. Importantly, pregnancy is also a time of social and economic change for a 
woman, her partner and her children. These changes are likely to be inter-related and have 
lasting effects on the future health, social and economic activity and wellbeing of the 
mother, partner and child. The birth of a child is also associated with changes to working 
patterns for both parents. Life Study will collect detailed information, pre- and post-birth, to 
allow analyses of how these critical labour supply decisions affect the future health and 
wellbeing of children. This will also include information on grandparents’ occupation and 
employment. 
Understanding how poverty and early child outcomes are linked will be vital. Measures of 
income and wealth, and parents’ subjective assessments of financial well-being will provide 
important information about the short- and longer-term financial resources available to the 
child. Information to be collected on parents’ educational qualifications and books in the 
home will provide an important measure of the cultural capital available to young children, 
which is an important contributor to children’s outcomes such as their readiness for school. 
6.7.1.1.5 Family structure and relationships 
The study will capture a comprehensive picture of the structure of the family into which the 
new child is born, and the stability of family composition in the first year of life. Parental 
relationship quality and stability are known to be extremely important determinants of 
children’s social and emotional development, and the birth of a new child typically puts 
pressures on intimate partnerships. This study will collect information on partnership 
dissolution and formation, and measures of relationship quality from mothers and partners 
during pregnancy. Maternal assessments of relationship quality will be collected at repeated 
time points, so the effects of changes from pre- to post-birth can be assessed in relation to 
the development of the child.  
The study will also collect repeated measures from the mother of the engagement of 
resident fathers and partners in household duties and child-rearing activities, and the 
degree of contact between the child and non-resident fathers. It is also anticipated that 
same-sex parents will be recruited to the study in significant numbers, allowing the first 
detailed analyses of parenting and child outcomes among this group. An enhancement to 
Life Study is also being developed, which will increase engagement with partners and 
fathers, and facilitate direct contact with this group after the birth of the child. 
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6.7.1.2 Infants 
Figure 2 sets out the topics within the ‘Infant’ module. These cover a wide range of 
information to be collected about the infant itself, his or her interactions with parents, 
childcare and the wider family, as well as pregnancy and childbirth. 
Figure 2: Infants - topics and question modules 
 
6.7.1.2.1 Pregnancy and birth 
Pregnancy is a metabolic challenge in which major changes to glucose and insulin 
metabolism and to vascular flow and function take place in order to ensure adequate 
nutrition for normal growth and development of the fetus. Extreme vascular and metabolic 
changes can result in diagnoses of pregnancy-induced high blood pressure or diabetes, 
which are associated with future adverse cardiovascular and metabolic disorders in the 
mother. It is unclear whether there are more subtle changes that are also associated with 
future adverse health outcomes in the child as well as the mother. Life Study will allow us to 
examine the association of weight, blood pressure, glucose, insulin and lipids in pregnancy 
with outcomes in the mother and child at 12 months after birth, as well as the extent to 
which any of these associations are related to socioeconomic or lifestyle factors, pre-
existing diagnoses, or if associations differ with maternal age, ethnicity or parity. 
Information will be collected about past maternal reproductive history, the current 
pregnancy (including pregnancy-induced complications) and information about the labour 
and delivery. Weight and body fat will be measured during and at 12 months after 
pregnancy (see anthropometry), and blood samples collected to allow measurement of 
glucose (glycated haemoglobin), as well as to allow additional analyses to investigate the 
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influence of maternal and fetal genotype and examine the influence of vitamin D sufficiency, 
iodine sufficiency and thyroid function during pregnancy on mother and child outcomes at 
12 months after birth. 
Around 1-2% of all babies born in the UK are the result of IVF and other assisted 
reproductive technologies (ART), thus the short and longer term health outcomes for 
children of these conceptions and their mothers is of key interest. ART is associated with 
increased numbers of multiple births which result in adverse pregnancy outcomes, 
mediated in part through prematurity. It is often difficult to determine whether adverse 
consequences are due to ART or related to multiple births, prematurity and the underlying 
reasons for the mother’s infertility. There have been virtually no useful large scale 
epidemiological research addressing the outcomes of ART in the UK, and Life Study 
represents an important opportunity to collect data on assisted conception and mother and 
child outcomes in a large longitudinal cohort. Changes in the legal framework governing the 
HFEA register offer an opportunity for record linkage. 
6.7.1.2.2 Child health 
Children’s health has long term impacts not only on their health and well-being in later life, 
but also impacts on other aspects of later life such as educational outcomes, employment, 
and income. Life Study affords both an opportunity to explore factors associated with poor 
health and also look longitudinally at outcomes associated with poor health during 
childhood. Life Study will gather information on the health of the infants starting from the 
immediate period after birth. Those who were born preterm, with congenital disorders, or 
required special or neonatal intensive care will be identified so that more detailed 
information on both the health problems and treatments required can be sought through 
record linkage. Life Study will include mothers’ views on the general health of the infants 
and whether they develop any longstanding illnesses. The study will also collect information 
on any health problems, which have either resulted in contact with a health professional or 
admission to a hospital, and medications taken regularly. More detailed information on 
children’s health will be obtained through record linkage to a number of ‘health’ related 
databases.  
Asthma is an important cause of reduced quality of life, use of health care services, long-
term use of medication and mortality across the whole spectrum of age, sex, ethnicity, 
socioeconomic status and geographical location. The prevalence of asthma increased over 
the last four decades of the 20th century with a stabilising over more recent years.  Whilst 
numerous theories have been put forward none adequately explain these trends. At an 
individual level, the most powerful risk factor for asthma is a history of atopic disease such 
as atopic eczema or allergic rhinitis. Life study will collect information on these conditions 
both in the infants and their families along with information on infections and immunity, 
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environmental pollutants and other factors of potential relevance. Such rich information 
may assist in developing our understanding of this important condition.  
In addition to physical measurements of vision in the infants and parents, mothers will be 
asked questions concerning the child’s vision and any problems. Mother’s and partners will 
also be asked about vision problems in their family and the treatments required.  Similar 
questions will be asked in relation to hearing problems.  
Immunisation is one of the key public health interventions for saving lives. Life study will 
gather an immunisation history plus mother’s reasons for their child not being up-to-date or 
rejecting vaccines. No other cohort has been able to look at the timeliness of immunisations 
so this will provide a unique opportunity.  Immunisation status and determinants of vaccine 
uptake are important to inform policy as well as being a marker of other health related 
behaviour and in particular of health beliefs. 
Injury remains one of the main causes of death and morbidity in childhood in the western 
world and accounts for significant health service utilisation. Infants younger than one year 
are particularly vulnerable because they are completely dependent on their caregivers for 
all their basic needs. Unintentional injuries are socially distributed and this socioeconomic 
gradient is far more marked amongst younger children. Most injuries to infants occur within 
the home environment. Life study will collect information on the frequency of injuries 
leading to medical attention and the nature of the injuries. This in conjunction with 
information about family circumstances and the home environment will help to inform 
policies for injury prevention.  
6.7.1.2.3 Child development 
Neuropsychiatric and developmental disorders in children are relatively common, often 
enduring and have high costs to individuals, families and society. Affected children are at 
higher risk of educational difficulties, with consequent implications for economic and social 
success in later life. Such disorders begin in infancy and early childhood and new tools are 
increasingly becoming available to diagnose these at an early age. Trends in cohort data 
over time reveal an increase in disruptive behaviour and emotional problems, including in 
autism spectrum disorders and attention deficit hyperactivity disorder (ADHD). Whilst 
neurodevelopmental and neuropsychiatric disorders have been a focus of earlier cohorts, 
no previous national cohort has covered the range of developmental disorders proposed for 
investigation in this study, nor have they undertaken prospective measurement of prenatal 
and early life precursors to childhood disorders. This study will include both paternal and 
maternal risk factors and use direct observational measures to supplement validated 
questionnaires.  
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Key areas of interest are: 
 Attention and cognition: Early attention and processing of visual stimuli has been shown to 
predict later cognitive ability or learning difficulties and to have implications for 
development of ADHD. 
 Emotion regulation: Infants’ early ability to regulate emotion in response to novelty and 
frustration appears to predict later emotional and behavioural disorders. 
 Communication and language: Infants’ early joint attention skills plus parental language 
appears to predict later language and communication abilities 
 Social interaction: Early parent-infant interaction, which promotes later emotional 
development and the ability to form close relationships. 
 
The six month visit will be adjusted for the child’s gestational age at birth by timing it from 
the estimated date of delivery at the 28 week pregnancy visit. This will ensure that babies 
who are born prematurely (before 37 completed weeks of pregnancy) will be invited to 
attend for developmental tests and observations at an appropriate stage of their 
development, and will be sufficiently mature to take part in the assessment activities. 
6.7.1.2.4 Sleeping and crying 
Around one-quarter of infants do not have a consolidated sleep pattern (‘sleep through the 
night’) by one year of age.  Night waking and related infant sleep problems have been 
associated with difficult temperaments and behaviour problems in younger children, poorer 
neurobehavioural functioning in older children and to parental stress. In Life Study, 
validated screening instruments will be used to characterise infant sleep patterns and 
identify sleep problems. This will support further investigation of the relationship with other 
measures of infant temperament, parent health and long-term outcomes. Infant crying 
behaviour has been associated with infant attributes, such as temperament, feeding and 
sleep patterns, as well as with extrinsic factors such as parent depression or anxiety. Life 
Study provides an opportunity to observe, in a longitudinal study of a normative population, 
the association of crying, sleeping and feeding routines in early life with factors such as 
parent and child interaction, the socio-economic and cultural environment and the infant’s 
intrinsic temperament.  
6.7.1.2.5 Diet and Nutrition 
Diet and obesity are important risk factors for a range of serious non-communicable 
diseases, including cancer, cardiovascular disease, and diabetes. Food choices are shaped by 
a complex interplay of individual, family and environmental factors. Life Study provides an 
opportunity to understand how key maternal factors, such as maternal diet, nutrition, 
eating habits and weight-related behaviours, may influence early childhood experiences 
related to diet and feeding,  as well as the long-term health outcomes for children. There is 
the additional opportunity to look at how these experiences, and the influences on them, 
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differ across ethnic, cultural and socio-economic groups. Specific attention will be given to 
feeding, including feeding intentions in pregnancy, the impact of wider social and family  
networks (such as grandparents) on feeding practices, duration of breastfeeding and 
weaning practices.  
The nutritional content of the diet will be investigated, particularly with regard to iodine 
sufficiency, Vitamin D sufficiency and the use of dietary supplements, and the implications 
of these for infant growth and development.  
Recent research from Southampton has also highlighted that up to 5% of households with 
young children may experience ‘food insecurity’, or limited/uncertain access to sufficient 
nutritious food. Children living in food insecure households have a poorer quality diet, with 
implications for long-term health and neurological development. Life Study will collect data 
to define food security across the UK population and to look at the long-term outcomes for 
children. 
6.7.1.2.6 Infections and immunity 
Microorganisms are an important environmental exposure that influences morbidity and 
mortality throughout childhood and later life. Life Study will address key questions about 
the role of infection and immunity as determinants of health, disease, well-being and 
development. The human immune response is influenced by infection and according to the 
timing of infection, the organism, host and microbe genetics and inherited or acquired 
immunity. Likelihood of infection and individual immune responses are affected by 
geography, culture and genetic profile. The timing of microbial colonisation of the newborn 
(particularly the gut microbiome) may have important implications for future health and 
disease. Only in recent years have the methods become available to investigate at scale the 
interaction between and the relative contribution of social, environmental, microbial and 
host factors in this complex process. Life Study offers a unique opportunity to explore the 
interplay of these processes from early life onwards.  
In addition to questions about infections, vaccinations and antibiotic use, specific biological 
samples will be collected at the Life Study Centre visit, at birth or retrieved from leftover 
stored samples (e.g. newborn bloodspot screening programme or maternity booking 
bloods).   
6.7.1.2.7 Parenting and childcare 
The sensitivity and responsiveness of parents and care-givers to their babies, and the quality 
of stimulation provided in the home and other settings, are known to be critical for young 
children’s development. In Life Study we will combine the piloting of innovative direct 
observational measures of mother-child interactions, with questionnaire instruments. The 
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questions are designed to capture maternal attachment (to the developing fetus during 
pregnancy, and then to the baby), maternal beliefs, attitudes and knowledge about infant 
development, and the frequency of activities such as singing and reading to the baby, and 
play materials in the home. 
For the mothers who return to work within the baby’s first year (around half of all mothers), 
the duration and quality of childcare arrangements are also important for the child’s 
development and well-being. This study will collect information about who looks after the 
baby, for how many hours each week, when this started, and the cost of childcare. Suitable 
measures of childcare quality will be used. 
6.7.1.3 Neighbourhoods and Environment 
Ecological theories suggest that a child’s development should be viewed as an evolving 
interaction between the person and the environment, and predicts multiple interacting 
influences on the child at the level of the family, the neighbourhood and the wider 
community. Figure 3 sets out the topics and question modules, grouped under 
Neighbourhoods and Environment. 
Figure 3: Neighbourhoods and Environment: topics and question modules 
 
6.7.1.3.1 Social networks 
Social support systems may either play a protective role, mitigating the effects of stress and 
other risk factors or create additional stressors through non-supportive, conflictual or 
interfering interactions. An innovation of this study, compared to other national and sub-
national birth cohort studies will be to collect information on both positive and negative 
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qualities of friendships and relationships with relatives, as well as capturing the way in 
which new technologies (such as social media networks) facilitate social interactions among 
mothers with young babies. Measures will be taken both for mothers and their partners.  
6.7.1.3.2 Neighbourhoods and housing conditions 
The study will collect information on potentially positive aspects of local areas in relation to 
parents and children, such as community-belonging, participation and trust, access to local 
area services and to green and open spaces. Many of these relate strongly to the social 
capital available to the family and child. Information on neighbourhoods can also be 
enhanced with detailed post-code level measures of deprivation, local labour market 
conditions and environmental factors. 
The study will also collect information on housing conditions, including measures that are 
likely to directly impact on child development, health and well-being, such as over-crowding 
and damp.  
6.7.1.3.3 Environmental pollutants 
Chronic exposure to potentially toxic substances in the environment is a fact of modern life. 
The environment and its possible effects on health have become major issues affecting 
public health and public perception of risk. During the prenatal period the baby is more 
sensitive and potentially vulnerable to harm from even small quantities of environmental 
toxicants, which can have lifelong impacts on health. In Life Study, the initial contact with 
participants during the mother’s pregnancy provides a unique opportunity to monitor 
environmental exposures in utero, and through the first year after birth. Questions relating 
to the environment and health will cover five exposure themes: air pollution, drinking water 
disinfection by-products, radio frequency and electromagnetic frequency exposure, 
persistent organic pollutants (particularly chemical exposures in the home), and noise.  
These will allow examination of hypotheses relating to the relationship between: 
 exposure to indoor and outdoor air pollutants (particularly arising from traffic) and 
risk of a) adverse birth outcomes and b) allergic and respiratory disorders 
 exposure to chlorination by-products in public water supplies and risk of adverse 
birth outcomes 
 radiofrequency (RF) exposure and a) adverse birth outcomes (low birth weight and 
congenital malformations), and b) cognitive development in early childhood 
 prenatal exposure and childhood dietary exposure to persistent organic pollutants 
(POPs), and longer term neurobehavioural/cognitive function in children, e.g. ADHD 
 the effect of noise exposure on longer term neurobehavioural/cognitive function in 
children. 
 Page | 111  
 
6.7.2 Piloting and revisions to the questionnaire 
NatCen, a fieldwork agency, was commissioned to pilot the Life Study questionnaire for the 
pregnancy component. Results from participant and interviewer evaluation led to changes 
to the final questionnaire and interview schedules. The pregnancy, 6-month and 12-month 
visit questionnaires were also longer than desired. The Life Study SSC reviewed and 
amended the questionnaires in the light of this experience and also the early experience of 
its use in the first Life Study Centre.  
Ipsos MORI, the fieldwork agency appointed to conduct the birth component, piloted the six 
month mother and resident father/partner questionnaires in 2015.  
All final versions are available from the ‘Resources’ page of the Life Study website.1  
 
 
 
                                               
1
 www.lifestudy.ac.uk  
